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ABSTRACT 
Despite recent advances in critical care, trauma still continues to be the leading cause of 
morbidity and mortality among individuals under 40 years of age and the third main cause of 
death throughout the world, carrying a substantial economic burden. Globally, the most 
common traumatic injuries are acquired through penetrating wounds, blunt injuries or burn 
mechanisms. Recent reports from the UK suggest a significant change in the demographics 
of major trauma. The typical major trauma patient is older, with a slight predominance of 
males, and with traumatic injuries resulted from falls from less than 2m in height. 
Mortality due to major trauma follows a biphasic pattern. Early fatalities occur due to 
haemorrhagic shock or brain injuries, whereas the late deaths (>5 days post-trauma) are 
attributed to progressive multiple organ failure (MOF) and sepsis postulated to result from 
dysfunctions of the immune system. Depending on the severity of trauma, the immune 
response can be over-active with uncontrolled release of pro and anti-inflammatory 
mediators causing multiple organ failure.  
This study focusses on the second-phase mortality induced due to major trauma. The 
hypothesis tested is that the late mortality and morbidity results from an imbalance of the 
pro and anti-inflammatory immune responses (SIRS and CARS) triggered after major trauma. 
While a balanced response of these two arms of the immune system result in homeostasis, 
the hyperactivity of the compensatory anti-inflammatory response (CARS) results in 
immunosuppression and increased risk of nosocomial infections and late onset MOF.  
The study is designed to investigate the role of IL-6, IL-10, IL-12 and IL-4 in the development 
of the late onset MOF with a view to evaluating their use as a predictive biomarker of poor 
clinical outcome. The data from the analysis of 80 major trauma patients show averaged IL-6 
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and IL-10 levels to decrease in major trauma patients from Day 1 to Day 5 post-admission 
(IL-6 p=0.000;  IL-10 p=0.000), while the trends for IL-4 and IL-12 increased over the same 
period for the cohort (IL-4 p=0.031; IL-12 p<0.001). When patients were clustered on the 
basis of Sequential organ failure assessment scores (SOFA) on Day 5 (cut off >3), statistically 
significant differences were observed in the Day 1 IL-10 and IL-6 levels at the cut off >3 for 
the respective SOFA score   (IL-10 p=0.023, IL -6 p=0.015) indicating a strong potential for 
their use as early biomarkers of poor clinical outcomes. The trends in Day 1IL - 10 and IL- 6 
concentration were maintained when the SOFA cluster cut offs were increased to > 6  (IL-10 
p=0.037; IL-6 p<0.001). When similar analyses were carried out with IL-12 data, a reverse 
trend was observed with higher Day 1 IL-12 levels being observed in the <3  Day 5 SOFA 
cluster, suggesting that high levels of IL-12 on Day 1 post-trauma is associated with good 
clinical outcomes downstream. Although the IL-12 data failed to show statistical significance 
at a SOFA cut off of 3 (p=0.268), when the data was clustered more stringently on a SOFA cut 
off of 6, the differences were statistically significant (p= 0.023). Similar trends were 
maintained for SOFA outcomes on Day 8. Similar to IL-6 and IL-10 patterns, high IL-4 levels 
on Day 1 post admission showed a significant association with poor outcome patient clusters 
on Day 5 (SOFA cut off 6; p=0.025)  
When cytokine levels were defined using Day 5 serum C-reactive protein concentration as a 
measure of poor outcome (rather than SOFA scores), similar trends were observed. 
However, the data was not statistically significant, possibly due to confounding factors 
resulting from a lower cohort size (n =30) where CRP records were available. In conclusion, a 
multiplex panel of these 4 cytokines may be of good predictive value for the early 
stratification of major trauma patients for focussed clinical intervention and improvement of 
clinical outcome.  
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CHAPTER 1: INTRODUCTION 
1.1 DEFINITION AND INCIDENCE OF TRAUMA: AN OVERVIEW 
Traumatic injury represents physical injuries of sudden onset which require immediate 
medical attention (Madar et al., 2018). Worldwide, there are approximatively 16,000 deaths 
per day resulting from traumatic injuries, with many more patients left with moderate to 
severe disabilities. Traumatic injury accounts for more deaths that malaria, tuberculosis and 
HIV combined (Lendrum & Lockey, 2012). Traumatic injuries resulted from road traffic 
accidents (RTAs) cost most countries 3% of the gross domestic product, with 93% of fatalities 
occurring in low and middle-income countries. Although traumatic injuries affect people of 
all ages, most at risk are young males in the 15-29-year-old group (Lendrum & Lockey, 2012; 
World health organisation, 2018).  
Every year in the United Kingdom, 16,000 fatalities occur due to traumatic injury. There are 
many more non-fatal injuries and an un-estimated number of people left with permanent 
disabilities requiring long-term rehabilitation following trauma (The trauma audit and 
research network report, TARN, 2018). The annual NHS costs for treating traumatic injuries 
is estimated at £ 1.6 billion (Lendrum & Lockey, 2012; The Royal College of Surgeons of 
England,2009).  
In a bid to improve trauma care services in the UK, the Department of Health in 2008 
published a report entitled “High quality care for all”, which resulted in the creation of 
specialised regional major trauma centres in the UK with responsibility for coordinating the 
management of patients with traumatic injuries in a particular healthcare region (Lendrum & 
Lockey, 2012). The programme aims to deliver treatment for everyone, around the patients’ 
needs, with 24-hour trauma teams available for pre-hospital intervention, emergency 
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department services and transfer to specialist surgical facilities. The regional trauma system 
oversees public health and injury prevention aspects, emergency medical services, major 
trauma centres, research and education with the aim of reducing death and disability 
following traumatic injury (The Royal College of surgeons of England,2009). 
The data collected regarding patient demographics, type of injury, interventions, 
observations, surgical procedures etc., are collated in a national website registry “Trauma 
audit and research network” (TARN) which is available for access through NHS trusts across 
England and Wales. TARN creates monthly and quarterly reports regarding the epidemiology 
and the level of trauma care within the hospitals, providing long-term metrics for trauma 
audit and research (The Royal College of surgeons of England,2009). 
Recent publications based on data from TARN, reported a major demographic change in the 
patterns of traumatic injury in the UK (Kehoe et al., 2015). While traditionally, major trauma 
was known to involve young males and road traffic injuries, the study reports that the typical 
major trauma patient is now older with a slight predominance in males and with the 
mechanism precipitating major trauma resulting from falls from < 2m in height. While road 
traffic collision injuries are related to younger patients, adults aged 60 and older account for 
more than 50% of severely injured patients (Kehoe et al., 2015, Trauma audit & research 
network, 2017). The predicted expansion in the ageing population and the existence of 
multiple co-morbidities in this cohort is likely to result in poorer outcomes and increased 
hospital stays with accompanying implications of increase cost burdens. An urgent review of 
the trauma care practices is therefore required to accommodate the changing demographics 
of major trauma in the UK.  
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1.2 PATHOPHYSIOLOGY OF TRAUMA 
Traumatic injuries can result from blunt, penetrating and burn mechanisms. They are caused 
by road traffic accidents, falls, occupational hazards, knife and gun injuries, sport injuries, 
natural disasters and many other physical injuries which require immediate care. The 
severity of the traumatic incident is clinically assessed using the Injury Severity Score (ISS) 
which combines the anatomical scores (Abbreviated Injury Scale) from multiple injuries in six 
allocated body regions (head and neck, face, chest, abdomen, extremity and external). The 
ISS is an internationally recognised metric which correlated to measure of severity including 
mortality, morbidity and hospitalization time (Lecky, Bouamra & Woodford, 2017). 
Following a traumatic event, the response of the body to the insult is to induce local and 
systemic inflammatory responses in a bid to restore homeostasis and to stimulate the repair 
mechanisms. A trimodal model distribution is recognised for mortality due to major trauma; 
in the early phase, the death occurs at the scene of trauma or shortly after arriving at 
hospital. Deaths due to major trauma occur in three phases, a) Immediate (45%) due to 
severe destructive injury, b) The second peak of early deaths can occur 24-48 hours after 
traumatic injury and accounts for about 10% of the death due to major trauma (Saadia & 
Schein, 1999; Sobrino & Shafi, 2013). c) Late phase death (45%), in the days or weeks that 
follow, primarily due to multiple organ failure MOF (Shafi et al., 2012).   
Advanced haemorrhage control and early resuscitation have significantly impacted on 
increasing survival rates in the early post-traumatic phase. Despite the recent developments 
in the fields of molecular medicine and Omics-based sciences significant gaps exist in our 
knowledge of posttraumatic molecular and immunological changes, we have yet to harness 
this knowledge in terms of applying it to impact patient management or improve patient 
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outcomes. Therefore, while advances in emergency care management have impacted 
favourably in reducing the first two phases, the third late phase peak continues unabated. 
Severe traumatic injuries can lead to acute traumatic ischemia of tissues. This is a 
consequence of blood loss due to injury to blood vessels as in open wounds, or at 
microcirculation levels due to oedema, as in blunt injuries or burns (Kemmer, 2006). The 
haemorrhage results in a lack of blood supply to organs with a redistribution of the blood to 
the heart and brain.  Insufficient oxygen delivered to the tissues leads hypoxia-induced to 
cell dysfunction and cell death (Michaels, 2004).Advances in the early trauma management 
protocols are directed at delivering rapid and effective resuscitation and fluid 
administration, with a view to improving the blood volumes, blood pressure and cardiac 
output (Goettler, Giannoudis & Rotondo, 2017). However, there is increasing evidence to 
suggest that reperfusion, through the release of free radicals and pro-inflammatory 
mediators, can result in further damage to the ischemic tissue, a phenomenon described as 
ischemic-reperfusion injury (Dorweiler et al, 2007). 
If ischemic-reperfusion injury is severe, the cells might undergo apoptosis or necrosis which 
will drive inflammation and the development of multiple organ failure, resulting in the late 
peak in mortality, the so-called “two-hit” hypothesis (Rostein, 2003). Ischemic reperfusion 
injury is an important clinical problem which can affect any organ system such as the brain, 
heart or skeletal muscle. Reactive oxygen species (ROS) and activated neutrophils are 
responsible for local and systemic damage caused by ischemic reperfusion which will 
manifest as systemic inflammatory response syndrome (SIRS) and multiple organ 
dysfunction syndrome (MODS) (Dorweiler et al, 2007; Gillani et al., 2011).  
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This process results in massive physiological changes, but the most important changes occur 
in the immune system. The first step of an inflammatory reaction to traumatic injury involves 
fluid phase mediators (cytokines, chemokines, coagulation and complement activation 
products, oxygen radicals, eicosanoids) and cellular effectors (neutrophils, 
monocytes/macrophages, and endothelial cells) that translate the trauma-induced signals 
into cellular responses (Huber-Lang & Gebhard, 2016). 
  
Figure 1: The response to traumatic injury (Costantini & Coimbra, 2017) 
 
Traumatic injuries cause physiological inflammatory reactions which activate neutrophils and 
macrophages through interaction with cytokines, chemokines and complement. Local 
inflammatory response, ischemic-reperfusion injury and tissue damage can induce a 
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systemic inflammatory response, even in the absence of invading pathogens (Fig 1). The 
systemic inflammatory immune response (SIRS) is triggered by the release of damage 
associated molecular patterns (DAMPs), coagulation and complement cascade, and by the 
innate immune cells activated by host tissue injury (Costantini & Coimbra, 2017; Hietbrink et 
al., 2016). 
1.2.1 Danger associated molecular pattern (DAMPs) 
The danger concept was first acknowledged by Matzinger in 1994, who stated that “the role 
of the immune system role is to detect and protect against danger and to discriminate 
between self and non-self. The way a cell dies dictates the activation or not of an immune 
response” (Matzinger, 1994). Endogenous molecules released by cells undergoing stress are 
referred to as alarmins and can be sensed by dendritic cells as danger signals and can trigger 
innate and adaptive responses (Fig 2). The alarmins are triggered either by cellular damage 
(damage-associated molecular patterns (DAMPs)), or conserved features of molecules found 
on bacteria or viruses (pathogen-associated molecular patterns (PAMPs)). Dendritic cells 
recognise foreign molecules through pattern recognition receptors (PRRs). Therefore, they 
recognise molecular features present on pathogens (PAMPs) as well as specific molecules 
generated as a response to trauma/stress or sterile injury (DAMPs) (Galucci, 2016). 
Tissue trauma, microbial toxins, excessive heat or radiation, ischemia, as well as diverse 
chemical stimuli can cause rupture of cells and release DAMPs acting as initiators of 
inflammation. As Figure 2 shows, DAMPs can activate tissue-resident macrophages, induce 
maturation of immature dendritic cells, and trigger production of cytokines, chemokines, 
and other factors responsible for neutrophils and monocyte/macrophages recruitment from 
peripheral blood (Martin, 2016).  
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DAMPs molecules are present intracellularly, therefore, the innate immune system cannot 
recognize them as they are sequestrated inside the cell. They can be released only when the 
cell undergo necrosis and intracellular content is released, signalling the death to innate 
immune system (Kono et Rock, 2008). The leaking of the intracellular proteins from the dead 
cells initiates an inflammatory response. They bind to host inflammatory cells via pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) and activate the complement 
cascade. (Rider et al., 2017).  
 
  Figure 2: The immune system activation (Martin, 2016) 
DAMPs include protein like heat shock proteins (HSP), high-mobility group box1 (HMGB1), 
monosodium urate (UA), Hyaluronan, adenosine, RNA/DNA, mitochondrial DAMPs, S100 
proteins interleukin-1α (IL-1 α) and interleukin-33 (IL-33), histones (Hirsinger et al, 2012). 
High mobility group box 1 protein (HMGB1), IL-1 α, IL-33 and S100 proteins have been 
studied extensively. They have dual-functions, both intracellular and extracellular and are 
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associated with beneficial housekeeping roles and tissue repair, being able to trigger a rapid 
inflammatory response (Berthelot & Latz, 2017). 
1.2.1.1 Heat-shock proteins (HSPs) 
HSP is one of the first endogenous molecules described to stimulate an immune response 
during sterile injury. HSPs play a role in intracellular trafficking, protein folding and 
maintenance of protein integrity. It is released from a variety of cell types, is present on the 
cell surface and can be found in serum (Feng et al, 2003). Purified HSPs have shown to 
trigger dendritic cell (DC) maturation and to stimulate their migration to lymphoid organs 
(Kono & Rock, 2008). However, Broere et al., (2011) considered that HSPs are not DAMPs as 
they are freely present in the extracellular fluid, as opposed to being released from the 
intracellular habitat in response to necrotic conditions. Moreover, HSPs seem to have a 
dampening effect on immune activation. The other school of thought supports the view that 
HSPs were mis-classified as DAMPs in earlier studies, due to contamination of recombinant 
HSP in lipopolysaccharides (Broere et al., (2011). 
1.2.1.2 High mobility group box 1 protein (HMGB1) 
HMGB1 is a DNA-binding nuclear protein with a role in modulating gene expression. HMGB1 
plays an important part in response to sterile injuries, such as haemorrhagic shock and 
ischemic/reperfusion injury. HMGB1 is released upon cell death, but it has also been shown 
that immune cells such macrophages and monocytes secrete HMGB1 in response to 
stimulation by cytokines or lipopolysaccharides (Hirsiger et al., 2012). Monocytes can also 
secrete HMGB1 due to complement activation product C5a, which plays an important role in 
sepsis and also in sterile injury. In severe trauma, the level of HMGB1 is proportional to the 
level of complement activation (Hirsiger et al., 2012). During apoptotic cell death, nuclear 
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HMGB1 is tightly attached to chromatin and is not released into the extracellular matrix, 
preventing an inflammatory response (Voll et al., 2008). However, upon tissue injury or cell 
necrosis, HMGB1 is released into extracellular space stimulating the production of tumour 
necrosis factor-α (TNF- α) (Kono & Rock, 2008). HMGB1 is considered a cytokine as it 
stimulates pro-inflammatory responses from monocytes/ macrophages. HMGB1 appears in 
the extracellular matrix 8-12 hours after the macrophage response to a pro-inflammatory 
stimulus (Andersson & Tracey, 2003), and can sustain the inflammation for several days. 
However, in sterile damage and tissue death, HMGB1 mediates early inflammation 
responses that only last hours (Bertheloot & Latz, 2017). 
1.2.1.3 Interleukin-1α (IL-1α) 
IL-1α is a dual-function cytokine that presents both nuclear and extracellular functions. 
Extracellular IL-1α has been shown to have an important role in sterile inflammatory 
diseases and in cancer (Borthwick, 2016). In resting cells, IL-1α is found in the nucleus and 
has a role in gene expression, acting as a transcription factor. It is continually expressed in 
epithelial cells, keratinocytes and fibroblasts, but is only released after loss of cellular 
integrity, like in necrosis. In non-sterile pathogen-associated cell damage, upon stimulation 
with LPS or TNF-α, IL-1α can also promote the expression of inflammatory cytokines IL-6 and 
IL-8 (Werman et al., 2004). IL-1 activates lymphocytes, monocytes and macrophages by 
inducing the production of inflammatory mediators. Studies on mice show that antibodies to 
IL-1α inhibited the immune response in sterile inflammation, sustaining the role of IL - 1α as 
a DAMP (Hirsinger et al., 2012). 
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1.2.1.4 Interleukin-33 
IL-33  is similar to IL-1α and HMGB1 regarding nuclear tissue expression and being released 
in extracellular matrix after loss of cellular integrity. It can also act as a cytokine and nuclear 
factor. IL-33 is expressed in structural and lining cells such as endothelial cells and the 
fibroblastic reticular cells of lymphoid tissues; it is also expressed by epithelial cells of tissues 
exposed to the environment (Moussion, Ortega & Girard, 2008). Similar to IL-1α and 
HMGB1, IL-33 may be released from dead or dying cells during trauma or infection and act 
as an alarmin to alert the immune system about cell or tissue damage. Mast cells, which are 
positioned close to endothelial cells of blood vessels and epithelial surfaces exposed to the 
environment, are the cellular target of IL-33 and may play an important role as an activator 
of mast cells during innate immune response to pathogens. The level of IL-33 in the serum 
increases during sepsis or trauma, acute myocardial infarction, idiopathic pulmonary fibrosis 
or asthma, (Moussion, Ortega & Girard, 2008).  
1.2.1.5 S100 proteins 
S100 proteins comprise 25 members with a large variety of functions. The role of S100 
proteins inside the cell is to regulate cell proliferation, differentiation, migration. It is also 
involved in Ca2+ homeostasis, inflammation and cell death. When released in the 
extracellular space, some S100 proteins act as DAMPs, initiating immune responses, cell 
migration, chemotaxis, but also tissue development and repair (Bertheloot & Latz, 2017). 
1.2.1.6 Mitochondrial DAMPs  
Mitochondrial DAMPs are made up of circular DNA strands containing CpG DNA repeats and 
were found to be elevated in severely injured patients (Hirsinger et al., 2012).  Mitochondrial 
DNA (mtDNA) retain molecular patterns similar to bacterial DNA, and when released into 
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circulation after traumatic injury, directly activate neutrophils via p38 MAPK pathway 
inducing an inflammatory response (Zhang, Itaqaki & Hauser, 2010).   
1.2.2 Haemorrhage and coagulopathies in trauma 
The most common cause of death after trauma is due to traumatic brain injury and/or 
haemorrhage. Coagulopathies following trauma are common and affect one in three 
severely injured patients; the bleeding is accountable for poor clinical outcomes and 
increased mortality (Cohen & Christie, 2016). Trauma induced coagulopathy (TIC) represents 
a serious secondary consequence of a traumatic injury. TIC can start as a consequence of 
tissue hypo-perfusion, showing that resuscitation after blood loss can have a significant 
adverse role in clotting (Tarmey & Kirkman, 2016).  
After an injury and haemorrhage, the body tries to achieve homeostasis.  It involves three 
stages comprised of vasoconstriction, platelet activation and blood clot formation (Palta, 
Saroua & Palta, 2014). Vasoconstriction is achieved through contraction of smooth muscles 
in the wall of the blood vessels with a role in narrowing the damaged blood vessels to reduce 
blood loss. One of the reactions of the body to blood loss in maintaining the homeostasis 
after cellular and vascular damage, is the production of thrombin. Thrombin is produced in 
less than 5 minutes after vascular damage and is the key to activating platelet aggregation, 
clot-formation, fibrin activation and activation of factor XIII, all essential processes in 
ensuring blood clot stability (Mann & Lorand, 1993). The activated platelets stick to each 
other and to collagen fibres from blood vessels and to Von Willebrand factor (vWF), forming 
a temporary blood plug. Platelets further release thromboxane A2 (TxA2) for platelet 
accumulation and vasoconstriction (Eisinger et al., 2018). The homeostasis is reached when 
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the blood clot containing fibres which trap platelets is formed, with the haemostatic plug 
acting to limit the leakage (Luyendyk et al., 2018).   
 
Figure 3: The coagulation cascade (Russel & Suarez, 2015) 
 
Thirteen coagulation factors are involved in three coagulation pathways, depending on the 
initial event which triggered the cascade (Figure 3). The extrinsic pathway starts when a 
vascular injury occurs, and tissue factor is released. The intrinsic pathway starts when 
damaged endothelium comes into contact with circulating blood, triggering a cascade of 
coagulation factors (XII, XI, IX and VIII). Both pathways converge in a common pathway 
where prothrombin and fibrinogen become activated and result in clot formation. Figure 3 
depicts the extrinsic, intrinsic and common pathways involved in the coagulation cascade 
(Russel & Suarez, 2015). In tissue injury, the cascade is initiated with the activation of factor 
VII(VIIa) by tissue factor (TF) from the cell membrane, as shown in Figure 3.  
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The clotting factors are precursors of proteolytic enzymes, zymogens, found in inactive form. 
Activated factor VIIa mediates the conversion of factor X to factor Xa. The intrinsic pathway 
is initiated when Factor XII auto activates and form F XIIa which activates prekallikrein (PK) 
liberating Kinins. Kinins are peptides which bind to receptors on many cell types and induce 
inflammation, vasodilation and vascular permeability. F XIIa and thrombin activate F XIa 
which activates factor IX, which further, together with cofactor VIII activate factor X. The 
common pathway beginning with factor X and V and calcium, converts prothrombin to 
thrombin, which will cleave circulating fibrinogen to fibrin, activating factor XIII, resulting in 
crosslinking fibrin polymers in the platelet plug (Palta, Saroa & Palta, 2014; Grant & Aird, 
2016).  
Patients suffering from blunt trauma and massive tissue injury have an increased thrombin 
generation, and soon after trauma many procoagulant particles are observed in the 
circulation (Hayakawa, 2017). In major trauma, trauma-induced coagulopathies can result in, 
hyper-fibrinogenolysis and consumption coagulopathy, characterised by disseminated 
intravascular coagulation (DIC). In severe trauma, the anti-coagulant pathway is impaired, 
plasma protein-C decreases, resulting in dysregulation of thrombin generation (Martini, 
2016). Hyper-fibrinogenolysis is controlled by enzymes t-PA which catalyse plasminogen to 
plasmin, which initiate fibrinogen degradation. Under normal physiological states, the blood 
coagulation is a dynamic process with clot formation, anticoagulation and fibrinolysis 
(Martini, 2016). In severe shock, endothelial cells will increase t-PA production, called “acute 
release of t-PA”. However, in traumatic injury, the activation of platelets with thrombin 
generation and clotting processes causes the consumption of the coagulation factors, 
leading to hypo-coagulation and hyperfibrinolysis. Another hypothesis is that activated 
protein-C is responsible for hypo-coagulation and hyperfibrinolysis observed in some trauma 
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patients (Martini, 2016). However, it was also observed that transfusions can lead to more 
dilution of fibrinogen leading to massive bleeding (Hayakawa, 2017). 
As shown before, major haemorrhage and coagulation abnormalities are of great concern 
regarding death in the first 24-48 hours after trauma. Furthermore, it has also been shown 
that coagulation and inflammation are inter-connected and can potential impact on each 
other (Tsao et al., 2015). The PAMPs appear to impact on coagulation. Upregulation of 
plasminogen activator inhibitor (PAI) trigger TLR-2, 2, 4 and 9 activations, can also result in 
increase of inflammatory cytokines production. Platelets are also known to be mediators of 
immune responses, as they express TLRs involved in immune response recognising PAMPs 
and DAMPs from damaged cells (Semeraro et al., 2011). 
DAMPs like extracellular histones have also been shown to have a massive pro-thrombotic 
effect, with fibrin and platelet deposition in lung alveoli and intra-alveolar haemorrhage. It is 
likely that they contribute to late multiple organ dysfunction in trauma. Platelets are also 
known to be mediators of immune responses, as they express TLRs involved in immune 
response recognising PAMPs and DAMPs from damaged cells (Semeraro et al., 2011). 
 1.2.3 Complement activation 
The complement system is a component of innate immunity and consists of a complex of 
approximatively 30 plasma proteins and cell surface proteins in inactive form. They are 
mostly produced by the liver and can be activated through pattern recognition or through 
pathogen-bound antibodies.  Complement activation leads to activation of an enzyme 
cascade (Huber-Lang & Gebhard, 2016). The complement proteins are proteases activated 
by cleavage of its zymogen precursor, which then cleaves its substrate (Janeway et al., 2001). 
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The complement system can be activated through four pathways: the lectin pathway, 
classical pathway, alternative pathway, and coagulation pathway (Amara et al., 2008). 
 
Figure 4: Complement activation pathway (Clos & Mold, 2008)  
 
1.2.3.1 Lectin pathway  
The lectin pathway is initiated by soluble carbohydrate-binding proteins such as mannose-
binding lectin (MBL) and ficolins which recognize and bind to carbohydrates on microbial 
surfaces such as PAMPs (Figure 4). MBL is present in low concentrations in plasma, but its 
production is increased during the acute-phase response, whereas ficolins are synthesized in 
the liver and circulate in the blood or are synthesized and secreted by lung and blood cells. 
These proteins are activated through cleavage by zymogens upon binding to pathogen 
surfaces, which further cleaves complement C4, releasing C4a and cause a conformational 
change in C4b. C4b then binds to C2, which is further cleaved producing C2a and will remain 
bound to C4b forming the complex C4b2a. C4b2a will cleave the molecule C3 in C3a and C3b. 
One molecule of C4b2a can cleave up to thousand molecules of C3. C3b binds covalently to 
a
a 
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pathogen surface, whereas C3a initiates a local inflammatory response (Beltrame et al., 
2014).   
1.2.3.2 Classical pathway 
Classical pathway is initiated via a pathogen sensor known as the C1 complex. C1 can 
interact with the pathogens, but also with antibodies. Because of this peculiarity, the 
classical pathway functions in both innate and adaptive immunity. The C1 complex is 
comprised of C1q, as shown in Figure 4, acting as microbial sensor and of C1r an C1s 
proteases in an inactive form. The activation of complex starts when C1q interacts with the 
pathogen, causing a conformational change in C1r-C1s complex, leading to activation of C1r 
which cleaves C1s, generating a serine protease. Following this step, activated C4 and C2 
form the active C3 convertase C4b2a, similar to the lectin pathway (Zhi & Skare, 2018). C1q 
can attach to the surface of pathogens and bind to C-reactive protein, however it mainly 
binds to Fc region of antibodies bound to pathogens, particularly IgMs-called natural 
antibodies. IgM binds C1q immediately after infection clearing bacteria before they become 
dangerous. Lectin and classical pathways result in opsonisation of the pathogens which 
make them easier to be detected by phagocytes (Murphy & Weaver, 2017). 
1.2.3.3 Alternative pathway 
The alternative pathway can get spontaneously activated by C3 convertase as shown in 
Figure 4, not the same as C4b2a convertase, shown in the previous pathways, but a C3bBb 
convertase which produce C3b. C3b can further generate more of itself, which together with 
the C3b generated by the previous pathways result in a large amount of C3b. The effect of 
complement activation is to generate and deposit large amount of C3b on the surface of the 
pathogens and trigger phagocytosis (Harboe & Mollnes, 2008). 
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 For phagocytosis to take place, complement protein C5 needs to be activated. C5 is 
activated by all 3 complement pathways producing C5a and C5b molecules. C5a complement 
fragments bind to C5a receptors on phagocytes and trigger the phagocytosis of the C3b 
coated pathogens. On the other hand, C5a and C3a initiate local inflammatory response by 
binding to specific receptors on endothelial cells and mast cells (Lachmann, 2018). The 
generation of large amount of these 2 complement fragments have shown to be connected 
to anaphylactic shock. Association of C5a and C3a leads to activation of mast cells to release 
histamines and TNF-α, and also can induce contraction of smooth muscles, vascular 
permeability inducing extravasation of immunoglobulins, complement molecules and 
phagocytic cells, initiating the adaptive immune response (Kemp & Lockey, 2002). 
Another effect of complement activation is the formation of the membrane-attack complex 
(MAC) that punches holes in the pathogen’s cell membrane destroying the pathogen, as 
shown in Figure 4. The formation of the complex starts with the release of C5b, which 
together with C6, C7, C8 and C9 form a pore in the pathogen membrane (Clos & Mold, 
2008). This pore formation is used only for killing of a restricted number of pathogens, 
making the opsonization and the triggering of inflammation the most important role of the 
complement activation (Murphy & Weaver, 2017).  
1.2.3.4 Complement system activation by the coagulation pathway 
Activation of the complement system takes place simultaneously with the coagulation 
response, one responsible for the innate immunity and the other to maintain the 
homeostasis in case of injury or pathogens invasion (Choi et al, 2006). Studies have shown 
that a new complement pathway has been found and is activated in absence of C3 molecule, 
with thrombin having C5 convertase activity and generating C5a.  These studies show that 
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there is a direct linkage between the complement and clotting pathways (Huber-Lang et al., 
2006). 
Most recent studies show that exposure to thrombin can also generate C3a as well as C5a. 
Excessive production of these complement molecules during severe tissue injury or systemic 
inflammation may contribute to attraction of phagocytes to the site of inflammation and 
release ROS, protease and cytokines which can have negative effects during systemic 
infection. A recent study by Amara et al., has found that there is an extensive cross-talk 
between the coagulation cascade and complement cascades. The coagulation cascade and 
complement system show to be simultaneously activated by severe tissue injury, acute 
trauma or during systemic inflammation, causing excessive generation of C3a and C5a. The 
formation of thrombin at the site of injury resulted from the activation of coagulation 
cascade, shows to trigger the complement system as well, with essential role for the 
protection against invading pathogens (Amara et al., 2010). 
1.2.4 Pattern recognition receptors (PRRs) 
Inflammation is the response of the body to eliminate harmful agents and to promote the 
regeneration of damaged tissue.  The phagocytes are a front-line defence strategy, detecting 
damaging substances released by microbes or dying cells through pattern recognition 
receptors (PRRs) such as toll-like receptors (TLRs) (Eom et al, 2018). DAMPs and PAMPs are 
released from stressed or infected cells and bind to specific receptors which will lead to 
initiation of a series of processes like cell differentiation, cell death or secretion of pro-
inflammatory cytokines. 
PRRs activate downstream signalling pathways that lead to the induction of innate immune 
responses by producing inflammatory cytokines like Type I interferon (IFN) and other 
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mediators which induce the maturation of dendritic cells. These processes trigger immediate 
inflammation as the host’s defensive response, but also initiate antigen-specific adaptive 
immune responses. These responses are crucial for the clearance of infecting microbes as 
well providing consequent instruction of antigen-specific adaptive immune responses 
(Kawasaki & Kawai, 2014). 
Toll-like receptors (TLRs), shown in Figure 5, are the first PRRs identified. They are able to 
recognise a large variety of PAMPs and DAMPs. TLRs are expressed on the cell surface or as 
intracellular vesicles or endosomes (Kumar et al, 2009). They are type I trans-membrane 
proteins with an ectodomain. It contains leucine-rich repeats that are involved in PAMP 
recognition, a trans-membrane region and cytosolic Toll-IL-1 receptor (TIR) domain that 
activates downstream signalling pathways, regulating the innate immunity and initiate 
adaptive immune responses. There are 10-12 types of TLRs, able to detect specific PAMPs 
from bacteria, viruses, mycobacteria, fungi and parasites (Kawai et Akira, 2011). 
Figure 5: Toll-like receptors (Godfrey et al, 2012) 
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TLR -2, -4, -5 and -10 are expressed on the surface of antigen presenting cells (APC) like 
macrophages and dendritic cells, whereas TLR-3, -7, -8 and -9 are present in endosomes (Liu, 
Zhang & Zhao, 2009). Receptors for advanced glycation end-products (RAGE), are pattern 
recognition of endogenous molecules which area multi-ligand receptors of the 
immunoglobulin family and play a critical role in innate immunity system. S100 protein 
family are ligands for RAGEs and are involved in chronic inflammation, neuro-generative 
disorders, tumour growth (Leclerc et al., 2009). HMGB1 is a ligand for TLR and RAG, whereas 
TLR2 and TLR4 are the major mediators for HMGB1 resulting in inflammatory cytokines 
secretion and production of nitric oxide (Komai et al., 2016). 
1.2.5 The inflammatory response to traumatic events 
Inflammation is a physiological process that is necessary for the tissue repair after traumatic 
injury. Inflammation is controlled by pro and anti-inflammatory processes, modulating or 
dampening down its effects in order achieve homeostasis (Choilean & Redmond, 2006). An 
uncontrolled pro-inflammation spread systemically resulting in systemic inflammation and 
resulting in tissues damage and organ failure. On the other hand, an over-active anti-
inflammatory response can take over resulting in a compensatory anti-inflammatory 
response (CARS). In this case the immune-paresis results system, dampening the ability of 
the immune system to react to a new danger signal. The result is hyper-susceptibility to 
microbial infections resulting in very serious complication like sepsis and multiple organ 
failure (Kimura et al., 2010). 
1.2.5.1 Innate immune cell activation 
In the first 10-15 minutes after injury, the initial vasoconstriction is followed by inflammation 
which manifests with erythema, heat and vasodilation. Inflammation is mediated by 
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endothelial mediators, leukotrienes, prostaglandins and histamines. Oedema is a sign of 
inflammation and is caused by leaking of plasma from the intravascular compartment into 
the interstitial compartment under the action of histamines, bradykinins, leukotrienes, 
complement, and platelet-activating factors. The increased vascular permeability has a 
positive role in facilitating the cells and inflammatory mediators to move easily to the site of 
injury (Hietbrink et al., 2006). 
 
Figure 6: Innate immune cell activation by tissue damage-generating DAMPs and infection- 
generating PAMPs (Lord et al., 2014) 
 
Infectious agents and traumatic injury can both trigger the initiation of an immune response. 
DAMPs can trigger a sterile inflammatory response, as in traumatic injuries, whereas PAMPs 
are triggered by exposure to exogen molecules (Figure 6). Both DAMPs and PAMPs are 
shown to stimulate complement activation, tissue factor expression on monocytes and 
activate innate immune cells leading to endothelial and organ damage or immuno-
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suppression, with release of more DAMPs in a vicious cycle of tissue damage and sepsis (Ito, 
2014). 
The innate immune system represents the first line of defence of the body triggered by 
exposure of neutrophils, monocytes, macrophages and dendritic cells to any exogenous or 
endogenous molecules (PAMPs and DAMPs). These host cells present on the surface protein 
receptors for PAMPs and DAMPs, known as pattern recognition receptors (PRRs) with role in 
initiation of inflammatory processes (Morgan, 2017). 
1.2.5.2 Neutrophils     
Neutrophils are the most abundant leukocytes in the human blood with a short life in a 
healthy individual. The main role of neutrophils is as host defence against rapidly dividing 
bacteria, fungi and yeast. Neutrophils are equipped with microbicidal defensive strategies, 
such as reactive oxygen species (ROS) production, degranulation, phagocytosis and 
neutrophil extracellular traps (NET) (McCracken & Allen, 2014). Tissue damage and 
haemorrhagic shock which takes place in traumatic injuries, induces ischemia and changes in 
metabolism. During reperfusion stage, the ischemic area is replenished with oxygen leading 
to radical oxygen species (ROS) formation. ROS have role of chemoattractant and activator 
of neutrophils and other polymorphonuclear granulocytes, which will be active in the area in 
the first 3 days after trauma (Kovtun, 2018). Neutrophils express on the surface pattern 
recognition receptors (PRRs); TLRs expressed on the surface are able to bind PAMPs and 
endogenous DAMPs resulting in neutrophil activation. HMGB1 can activate neutrophils by 
binding to their TLR2, TLR4 and RAGE receptors, leading to upregulation of pro-inflammatory 
cytokines, such as IL-1β, IL-8 and TNF-α. Similarly, mitochondrial DAMPs released in 
circulation during trauma, increased the adherence of neutrophils to endothelial cells, 
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through upregulation of adhesion molecule I-CAM1 and E-selectin on endothelial cells, and 
through L-selectin and CD18 on neutrophils surface, contributing to increased endothelial 
permeability present in SIRS (Hazeldine, Hampton & Lord, 2014).                                                                     
The first impact of neutrophils with tumour necrosis factor alpha (TNF-α) and granulocyte 
macrophage colony stimulating factors (GM-CSF) present in the peripheral blood of injured 
patients results in a pre-activation of neutrophils with enhanced functions like in 
chemotaxis, adhesion, rolling, diapedesis, extravasation and oxidative burst. Enhanced 
oxidative burst make neutrophils to have an increased cytotoxic potential, which might lead 
to incontrollable cytotoxicity and result in SIRS or multiple organ failure (MOF). The most 
elevated values of oxidative burst were found to be between day 2 and 5 after trauma, 
however, sometimes the values remain elevated until day 13 (Hietbrink et al., 2006). 
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1.2.5.2 Monocytes 
Blood monocytes are precursors of macrophages, dendritic cells and osteoclasts (Figure 7). 
Monocytes originate from bone marrow and continuously enter the blood circulation. 
During injury or inflammation, the monocytes invade the inflamed tissue and participate in 
immunological response removing the microorganisms, the debris and dead cells, and 
participate in tissue healing.  
The differentiation of monocytes in scavenging macrophages or antigen presenting dendritic 
cells is dictated by the environmental signals at the site of inflammation (Spangers, de Vries 
et Everts, 2016; Ingersoll et al., 2011). Interferon γ (INF- γ) and Interleukin-6 (IL-6) stimulate 
monocytes to differentiate into macrophages, whereas tumour necrosis factor (TNF) 
presence induces monocyte differentiation in dendritic cells (DC) (Delneste et al, 2003; 
Chomarat et al, 2003). 
             
 Figure 7: Monocyte differentiation. (www.lonza.com, 2018)  
 
The monocytes secrete several inflammatory mediators, such as TNF-α, IL-1β, IL-6 and IL-8 
which are used in many studies as biomarkers for early detection of organ dysfunction in 
patients who suffered severe traumatic injury. Studies have found that after traumatic injury 
the monocytes are hyper-activated, but this state is rapidly replaced by a paralysis in cell 
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function which alter cytokines production with potential fatal immunologic outcome. 
(Bhardwaj et al, 2018; Kirchhoff et al, 2009). 
Macrophages produce a large amount of pro-inflammatory cytokines in response to danger 
signals, which in some situations can trigger a cascade of inflammatory mediators, leading to 
tissue destruction. Mainly, macrophages synthesise TNF, Il-6, IL-12 and interferons 
(Hamidzadeh et al., 2017). 
Dendritic cells (DC) are the key for linking the innate immune response to adaptive immune 
system. They initiate the antigen-specific immune response generating specific T-cells as 
response to pathogens. Dendritic cells recognize the pathogens due to receptors present on 
their membrane; they bind peptides belongings to degraded pathogens and present them to 
T-cells to activate them and induce their proliferation (Collin & Bigley, 2018). In addition, 
dendritic cells also secrete pro-inflammatory cytokines, such as IL-12, fundamental for T-cell 
stimulation and differentiation. Mature DC enter the lymph nodes and starts production of 
antigen-specific memory T-cells. Apart from conventional DCs, another type of DCs are 
identified and known as plasmacytoid DCs; they respond to virus infection and secrete type I 
interferons (Mellman, 2013; Collin & Bigley, 2018).  
1.2.5.3 Leukocytes transendothelial migration 
To initiate an immune response, either from the innate or from adaptive immune response, 
the leukocytes need to cross the blood vessels. The extravasation of leukocytes takes place 
through an elaborate mechanism which includes adhesion between leukocytes and 
endothelium, diapedesis and traverse the endothelium, followed by migration towards the 
site of damage. A large array of molecules is involved in this process. The inflammatory 
response starts at the site of injury with in haemodynamic changes in post capillary venules 
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resulting in reduced blood flow rate (Schnoor et al., 2015). This event facilitates the 
leukocytes to make a close contact with the endothelial cells. All leukocytes require the 
activation of LFA-1 leukocyte integrins; neutrophils and monocytes require Mac-1 activation; 
monocytes, eosinophils and effector T and B cells requires activation of VLA-4 integrins 
(Nourshargh & Alon, 2014). Neutrophil extravasation will be taken as example for all 
leukocytes transendothelial migration, as shown in Figure 8. 
 Normally, neutrophils make only temporary and reversible contact with the endothelium at 
a velocity of 40 µm/s through endothelial P-selectins and neutrophils’ receptors, as seen in 
Figure 8. Histamines promote the translocation of P-selectin from Wiebel-Palade bodies in 
the luminal side of endothelial cells interacting with the counter-receptors on leukocytes 
(Hyun, Lefor & Kim,2009) . The on-off binding process is very rapid in a rolling-like manner. 
Due to inflammatory signals, the endothelial cell will express more surface adhesion 
molecules E-selectins providing more binding sites for neutrophil receptors; now, the speed 
of the neutrophils is decreased to 5 µm/s. E-selectin helps to bring the neutrophils closer to 
endothelial cells where they will enter in contact with other chemokines, inducing a 
conformational change in β2-integrin LFa-1 on neutrophils (Hyun, Lefor & Kim, 2009; Muller, 
2013).  
 Integrins are adhesion receptors found in resting state in inactive conformation at low 
affinity state. They are inside-out signalling molecules stimulated by chemokines. 
Leukocytes’ integrins consist of β2-subunits coupled with several α- subunits. The integrins 
bind to endothelial ICAM-1 and VCAM-1 resulting in a strong and firm arrest of the 
neutrophils at endothelium surface (Figure 8, point A - adhesion). Mac-1 integrins on 
neutrophil surface binds to endothelium PECAM-1 and traverse through the endothelial cells 
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(Figure 8, point B – transmigration) travelling to the site of inflammation (Futosi, Fodor & 
Mocsai, 2013). Out of the blood vessels, neutrophils bind to extracellular matrix receptors 
inducing activation of intracellular signalling pathways, resulting in increased chemotaxis and 
chemokinesis (Miralda, Uriate & McLeish, 2017).  
Neutrophils migrate towards the site of interest following the concentration gradient of 
chemoattractant such as bacterial peptides, anaphylatoxin complement C5a, platelet 
activation factor (PAF), IL-8 or leukotriene B4 (LTB4) or other inflammatory molecules. IL-8 
might contribute to mobilization of immature and less deformable neutrophils from the 
bone marrow which can create side effects by getting trapped in distal organs. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Neutrophil migration (Miralda, Uriate & McLeish, 2017)  
  
The next step is the binding of neutrophils to opsonised pathogens, then phagocytosis and 
degranulation of antimicrobial factors. Phagocytosis and formation of the phagosome trigger 
intra-phagosomal release of antibacterial peptides, proteases myeloperoxidase and 
superoxide anion (O2). Superoxide anion initiate the generation of reactive oxygen species, 
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called respiratory burst, with result in annihilation of bacteria trapped in the phagosome 
(Figure 8, point F and G), followed by apoptosis of neutrophils (El-Benna et al., 2016). 
 Another defence mechanism of neutrophils is the formation of a web-like structure called 
neutrophils extracellular traps (NETs), known as NETosis (Figure 8, point E) made up of 
chromatin, HMGBI1, histones, and antimicrobial proteins (Lipinska-Gediga, 2017). McIlroy et 
al (2014); Hamaguchi et al (2013) show that NETs formation is characteristic to critically ill 
patients and develop after major trauma in patients with systemic inflammatory response 
syndrome (SIRS).  
1.2.5.4 Vascular changes that allow the migration of the lymphocytes 
The transmigration of lymphocytes from vascular lumen require interaction with the 
endothelial cells (EC), pericytes and basement membrane (BM). This process takes 
approximatively 20-45 minutes. The transmigration generally starts with a pore formation 
within endothelial cells junctions, followed by sub-endothelial crawling along pericytes until 
they reach a zone of low matrix proteins (i.e. Laminin 10 and collagen type IV) in venular 
basal membrane, known as low-expression region (LER). They present as gaps between 
adjacent pericytes which are used as gates to penetrate the vessel wall and to migrate at the 
site of inflammation (Wang et al., 2006; Voisin & Nourshargh, 2013). The gap formation 
between pericytes are induced by pro inflammatory cytokines such as TNF-α and IL-1β 
through interaction with their corresponding receptors expressed on the surface of the 
pericytes (Proebstl et al., 2012). 
1.2.6 Acute phase response (APR) 
APR is part of the innate immune response against potential pathogens, however can be also 
induced by various physiological changes resulted from trauma or stress. APR initiate an 
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inflammatory process comprised of pyrexia, leucocytosis and hormone alteration, with role 
in enhancing the healing process and establishing homeostasis. (Cray, Zaias & Altman ,2009). 
During the APR, the liver secretes plasma proteins called acute phase protein (APP) as shown 
in Figure 9. However, recent studies have found that APP can be expressed also by other 
tissues and secreted into interstitial fluids (Schrodl et al., 2016).  
The production of APP from hepatocytes is induced by systemic release of inflammatory 
cytokines such as IL-1, IL-6 and TNF-α from macrophages and monocytes at the site of injury 
or infection. However, IL-6 is the major mediator responsible for hepatocytic secretion of 
most of APPs (Jain, Gautam et Naseem,2011). The peak of concentration is reached within 
24-48 hour after injury and decline when the infection recedes. Acute phase proteins are 
used in diagnostic medicine and prognosis of cardiovascular diseases, organ transplant or 
autoimmunity. Upon stimulation from cytokines, the hepatocytes increase the synthesis and 
release of positive acute-phase proteins, including C-Reactive protein (CRP) (Figure 9). IL-6 is 
the major cytokine stimulus for CRP production. (Hengst, 2003). CRP was the first APP to be 
described and it is used as a marker for infection, trauma, autoimmune diseases or 
malignancies. 
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Figure 9: Stimulation and synthesis of positive acute-phase reactants during inflammation (Hengst, 
2003). 
 
Other APPs are serum amyloid A (SAA) and serum amyloid P (SAP). They are considered as 
major APP, and each one has a distinct physiological function for the immune system (Gruys 
et al., 2005). 
 CRP can bind to polysaccharides on bacteria or parasites and activate complement system 
and phagocytosis; moreover, CRP upregulate or modulate secretion of cytokines and 
chemokines. In addition to CRP, SAA has role in chemotaxis of monocytes, PMCs and T-cells 
and down-regulate the inflammatory process. (Cray, Zaias & Altman ,2009). Other APPs are 
coagulation proteins (fibrinogen), haptoglobin which is a transport protein with 
bacteriostatic effect and inhibitor of neutrophils respiratory burst activity, and complement 
protein(C3) (Jain, Gautam & Naseem, 2011). 
C-reactive protein (CRP) is an acute-phase protein which increases rapidly in response to a 
traumatic event. Generally, the levels of CRP range between 0.1 and 10 mg/l. The levels of 
CRP increase very fast in response to a traumatic event, infection or inflammation (Lee et 
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al.,2005). Levels higher than 90 mg/l were found to align with surgical complications 
(Neumaier & Scherer, 2008), whereas CRP levels higher than 100mg/l were correlated with 
sepsis (Povoa et al., 2005). CRP is known to have a short life, meanings that higher levels of 
CRP maintained for days after a traumatic event may show an ongoing inflammation which 
can lead to sepsis. (Lee et al.,2005). 
1.3 THE ADAPTIVE IMMUNE RESPONSE  
The innate immune system provides the first line of defence against various microorganisms 
or foreign molecules. However, the innate immune system cannot eliminate all pathogens 
and foreign invaders. In this situation, the adaptive immune system gets activated and 
provide more protection against these threats. The major components of adaptive immune 
system are B-lymphocytes (B-cells) and T lymphocytes (T-cells), the first is responsible for 
humoral immunity represented by B-cells, whereas T-cells mediate cell-mediated immunity 
(Schenten & Medzhitov, 2011). 
The bigger player responsible for the connection between the innate immune system to 
adaptive immune system is represented by dendritic cells (DCs) which carry pathogen 
antigens-peptide on MHC class I or II (Figure 10), then present them to T lymphocytes 
(Janeway, Travers & Walport, 2001). The role of the DC is crucial, and the efficiency of the 
immune response depends on pathogen recognition and presentation to other cells of the 
immune system (McCullough, Ruggli & Summerfield, 2009). 
After DCs activation they migrate to lymph nodes presenting their antigen to T-cells and 
initiating an adaptive immune response. Once the T-cells are activated they differentiate in 
effector cells. Factors such as adhesion molecules and cytokines produced by DCs dictate 
which type of effector cells they become. 
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Figure 10: Initiation of the adaptive immune response by antigen presenting-dendritic cells  
(Medzhitov & Janeway Jr, 2000). 
 
DCs can express IL - 12, IL - 1, IL - 6 or IL - 18 and interferon-gamma (IFNy). They are known 
to induce naïve T cells to express T- bet and STAT 4 and STAT 1 and to differentiate towards 
T helper 1 (Th1) cells as shown in Figure 11. Viruses or bacteria can induce a Th1 response by 
activating natural killer cells. 
In contrast, allergens and parasites induce T helper 2 (Th2) responses via the release of IL - 4 
with possible involvement of eosinophils and mast cells; it also induces naïve T cells to 
express STAT 6 and GATA3 and to differentiate in Th2 cells (Lee &Iwasaki, 2007; Zang et al., 
2014). 
T-box transcription factor (T-bet) is the master regulator of Th1 differentiation through 
activation of a set genes which promotes only the differentiation towards Th1 phenotype 
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and suppress the development of Th2 phenotype, impairing the function of transcription 
factor GATA3 (Luckheeram et al., 2012). 
 
Figure 11: Th1 and Th2 differentiation (Carbo et al, 2013) 
 
Th1 and Th2 cells undergo differentiation through help derived from cytokines, DC, 
macrophages, and other cell types. Th1 cells are activated by IL - 12 and IFNy and inhibited 
by IL - 4, whilst for Th2 cells the reverse is true. (O’Garra & Arai, 2000). 
In addition to Th1 and Th2 cells, and depending of environmental factors, naïve T cells can 
differentiate in other subsets of T cells, such as Th17 and T regulatory (Treg) cells, and also in 
Th9 and T follicular-helper cells. The cytokines present in the environment are the major 
inducers of differentiation in different subsets. As already shown in Figure 11, Th1 
differentiation is coordinated mainly by IL - 12 expressed by macrophages and DC, whereas 
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Th2 differentiation is driven by IL - 4 presence. Th2 cells express themselves IL - 4 and IL - 10 
which antagonize Th1 development (O’Garra & Arai, 2000).  
T helper cells are seen as the most prolific cytokine producers. Th1 cells express cytokines 
such as IFN-y which promotes pro-inflammatory responses. IFN-y enhances IL-12 production 
directly and further, more Th1 cells generation. On the other hand, Th2 cells express 
cytokines such as IL - 10 and IL - 4, which modulate pro-inflammatory response, and are 
known as anti-inflammatory cytokines (Berger, 2000; Osugi et al., 1997). 
 1.3.1 What are the cytokines?  
Cytokines are hormone-like polypeptides comprising of a family of soluble proteins with a 
fundamental role in facilitating communication between cells and external environment. 
Under the term of cytokines comes lymphokines, monokines, interleukins (IL), interferons 
(IFN), tumor necrosis factor (TNF), chemokines and colony stimulating factors (Zhang & An, 
2009). They are secreted mainly by white blood cells; however, it was found that fibroblasts, 
epithelial cells or endothelial cells can also express a variety of cytokines.  
The most prolific producers of cytokines are T helper cells (Th) and macrophages They 
regulate the immune system through immune cell differentiation and proliferation, but also 
have role in the regulation of inflammation and in haematopoiesis. The cytokines bind to 
specific receptors on the cells, inducing signal transduction and initiating gene transcription 
which results in translation of proteins which can change cell’s function or characteristics 
(McInnes, 2017). The cytokines are pleiotropic, redundant and multifunctional. They 
regulate the response to infection, inflammation, or trauma. There are proinflammatory 
cytokines and anti-inflammatory cytokines. The anti-inflammatory cytokines antagonize pro-
inflammatory types by reducing inflammation and promoting healing (Dinarello, 2000). 
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The pleiotropic function of cytokines can be observed in figure 12, showing that one single 
cytokine can affect the activity of multiple cell types. The redundancy characteristic of 
cytokines means that multiple cytokines can have similar effects on one type of cell. These 
functions are possible due to the ability of certain cytokines to bind to multiple types of 
receptors or by the ability of many types of cytokines to bind to same receptor (Nicola, 1994; 
Ozaki & Leonard, 2002). 
 
Figure 12: The cytokine network. The figure depicts how each cell of the immune system secretes 
multiple cytokines which further induce other immune cells to express other type of cytokines (Zhang 
& An, 2009) 
1.3.2 Pro-inflammatory cytokines 
Proinflammatory cytokines are secreted mainly by activated macrophages, instigating an 
inflammatory reaction. IL - 1β, TNF-α, IL - 6, IL - 12 are the most important pro-inflammatory 
cytokines. 
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1.3.2.1 Interleukin - 1 (IL - 1) 
Interleukin-1 consists of two major proteins, IL - 1α and IL - 1β which are important 
mediators of inflammatory responses. IL - 1 is secreted by monocytes and macrophages and 
by fibroblasts and endothelial cells as result of cell injury, infection or inflammation 
(Dinarello, 2018). Traumatic injury results in ischemia, hypoxia and necrosis. IL - 1α in 
precursor form is released from necrotic cells contributing to infiltration of neutrophils and 
initiation of sterile inflammation. It acts as an alarm signal in tissue injury and it is rarely 
secreted (Rider et al, 2011). IL - 1β is associated with pain, autoimmune conditions and with 
inflammation. IL - 1β promotes macrophages recruitment. Unlike IL - 1 α, IL - 1β is not 
expressed in homeostatic conditions. It is present in the inactive state in inflammasomes, 
where it can be activated by the cleavage of its precursor during inflammatory processes. 
Comparing IL - 1α with IL - 1β, the latter is dominant in later stages of inflammation and is 
involved in propagation of the inflammatory response. IL - 1 α released from dying cells 
initiate sterile inflammation inducing the recruitment of neutrophils, whereas IL - 1β 
promotes the recruitment and retention of macrophages (Rider et al., 2011). 
1.3.2.2 Tumour necrosis factor-α (TNF - α) 
TNF - α is a pleiotropic pro-inflammatory cytokine produced mainly by monocytes and 
macrophages. It can also be secreted by other non-immune cells such as smooth muscle 
cells, fibroblasts or neurons, microglia and astrocytes. TNF - α plays an important role in the 
inflammatory response to injury by recruiting immune cells such as macrophages and 
neutrophils at the site of injury. It acts as an acute-phase protein initiating a cascade of 
cytokines and growth factors (Liu & Tang, 2014; Woodcock & Morganti-Kossmann, 2013). 
High levels of TNF - α were detected in the first 4 hours after traumatic injury, after this time 
its values decreases rapidly. Animal model studies showed that there is a correlation 
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between high systemic concentration of TNF and the mortality due to haemorrhagic shock 
(DeLong & Born,2004).  Anti-TNF - α therapies were successfully used as treatment for  
rheumatoid arthritis or inflammatory bowel disease. However, clinical trials involving 
approximatively 1000 patients with sepsis treated with TNF-neutralizing antibodies did not 
show any improvement in the 28-day survival rates, and more research is needed in this 
field. (Dinarello, 2000). 
1.3.2.3 Interleukin- 6 (IL - 6) 
IL - 6 is a small glycoprotein(21kDa) with four-α-helix-bundle structure, identified in mid-
1980. IL - 6 is present in the blood of heathy individuals at as low as 1-5 pg/ml. Its levels can 
rise considerably during inflammatory events such as sepsis, when their concentration can 
be measured at levels of µg/ml. IL - 6 generation is activated by tissue damage or stress, 
such as ROS, also by the presence of lipopolysaccharides (LPS) or viral products. IL - 6 is also 
activated by pro-inflammatory cytokines TNF - α and IL - 1α which activate NF - kB binding 
site on the promoter region of IL - 6 gene, shown to have an important role in the 
inflammatory response to infection and tissue injury (Liberman & Baltimore, 1990).  
 Initially, IL - 6 was identified as B-cell differentiation factor inducing terminal B-cell 
differentiation and production of immunoglobulin G, (Figure 13). IL - 6 was also known as 
hepatocyte-stimulating factor for its capacity to induce acute-phase proteins production, 
such as C-reactive protein (CRP), β2-fibrinogen, amyloid or haptoglobin (Kishimoto, 2010). It 
has pro and anti-inflammatory proprieties, regulating the balance between regulatory and 
effector T-cells. IL - 6 orchestrates innate and adaptive immune response through regulation 
of the acute phase response, hemopoiesis and inflammation. IL - 6 is secreted by a variety of 
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cells, such as macrophages, dendritic and T-cells. However, B-cells, endothelial cells, 
fibroblasts, astrocytes and epithelial cells were shown to secrete IL - 6 as well.  
IL - 6 is secreted by macrophages, monocytes, T-cells and endothelial cells, and released 
early after trauma. Its role is to initiate the hepatic acute-phase response, stimulating C-
reactive protein (CRP) and other acute-phase proteins is necessary to promote an 
inflammatory response. There is evidence in scientific literature to suggest that the pattern 
of expression of IL - 6 in trauma correlates to severity of the injury Moreover, it was found 
that high levels in IL - 6 was common in non-survivors (Strecker et al., 2003; Okeny et al., 
2015). 
 In the acute phase of inflammation, the IL - 6 pro-inflammatory effect was found to have an 
important role in initiating the systemic inflammatory response and was used as an early 
biomarker of severity of injury in trauma patients. The IL - 6 anti-inflammatory effect acts as 
down-regulator for TNF - α and IL - 1 secretion (Mihara et al, 2012; Rincon,2012; Stensballe 
et al., 2009).  Increased levels of IL - 6 in the acute phase response or wound healing is 
considered protective in the short term, only when the response becomes chronically 
activated, then high concentrations of IL - 6 can become pathogenic to the host, being 
associated with fibrosis and chronic inflammation (Fontes et al., 2015).   
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Figure 13: Biological activity of IL 6 and its effect on cells and organs ( Rincon, 2012)  
 
The presence of IL - 6 during antigen stimulation of CD4 T- cells, promotes a shift in Th1/Th2 
balance towards Th2, acting like IL - 12 on naïve CD4 T-cell differentiation. Moreover, IL - 6 
promotes autocrine production of IL - 4, and further, increases the Th2 differentiation 
through an auto-feedback loop (Dienz & Rincon, 2008). IL - 6 has proved to have an 
important role in the progression of auto-immune diseases, and its excess in serum levels is 
correlated to several chronic inflammatory diseases such as systemic lupus erythematosus 
(SLE), rheumatoid arthritis and multiple myeloma (Maeda et al, 2010). IL - 6 is part of the IL - 
6 family which also includes IL - 11, leukaemia inhibitory factor (LIF), oncostatin M (OSM), 
ciliary neurotrophic factor (CNTF), cardiotrophin-like cytokine (CLC) and cardiotrophin-1 (CT-
1). 
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IL - 6 acts upon the cells which express IL6 receptors (IL-6R), predominantly leukocytes and 
hepatocytes.  IL-6R is an 80 kDa transmembrane protein with a short cytoplasmic domain, 
first identified in 1988.               
IL - 6R exist as membrane-bound form and as a soluble form sIL - 6R. IL - 6 which bind to 
membrane-bound receptors is known as IL-6 classic signalling, whereas when binding via 
soluble IL - 6R, is known as IL - 6 trans signalling. IL - 6 binds to IL-6R and gp130, activating 
JAK/STAT pathway. STAT3 become phosphorylated forming homodimers which translocate 
to nucleus where regulate gene transcription (Heinrich et al., 1998).  IL - 6R is mainly 
expressed on hepatocytes and many leukocytes, whereas sIL-6R is present in blood and 
urine, with concentration in serum around 25-35 ng/ml (Wolf et al, 2014). IL-6 binding to 
membrane-bound IL - 6R associates with the signal-transducing β-subunit glycoprotein 
gp130 (130kDa) which serves as signal transducer and formation of high affinity IL - 6 binding 
sites (Hibi et al., 1990).       
IL-6 signals via the activation of Janus kinases (Jaks) and transcription factors of STAT family, 
known as the Jak/STAT signalling pathway (Fig 14). IL - 6 induces gp 130 homodimerization; 
gp-130-associated kinases Jak1, Jak2 and Tyk2 becomes activated and the cytoplasmic tail of 
gp 130 is phosphorylated. Phospho-tyrosine residues of gp 130 are docking sites for 
transcription factors STAT3 and STAT1, which become phosphorylated. They form dimers 
and translocate to the nucleus where they regulate the transcription of targeted genes, such 
as APP genes for C-reactive protein, lipopolysaccharide-binding protein, interferon 
regulatory factor or interstitial collagenase, and many other varieties of genes (Heinrich et 
al., 1998). 
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1.3.2.4 Interleukin - 12 (IL - 12) 
IL - 12 is a cytokine, a 70kDa hetero dimer, composed of a light α-chain of 35 kDa (p35 
subunit) and a heavy unit 40 kDa β-chain (p40 subunit). IL - 12 was first described in 1989 by 
Kobayashi et al. It was first known as natural killer cell stimulatory factor (NKSF) for its 
capacity to induce interferon-gamma (IFN - γ) production from T and NK cells (Oshimi & 
Hoshino, 1992). IL - 12 was also known to increase cytotoxic activity of resting peripheral 
blood NK cells as cytotoxic lymphocyte maturation factor (CLMF) for its proprieties as growth 
factor for activated T-cells (Gubler et al., 1991).  
IL - 12 is an activator of cell-mediated immunity and promotes the differentiation of naïve 
CD4+ Th cells into Th1 cell, being an important link between innate and adaptive immunity. 
IL - 12 induces the proliferation of cytotoxic T lymphocytes, B cells and NK cells and is 
produced by activated dendritic cells and phagocytes (Shaashua et al., 2013). IL - 12 induces 
T cells and NK cells to produce several cytokines, the most important of them being IFN-γ 
(Trinchieri, 2003). In traumatic injury, a depressed IL - 12 production is correlated with a shift 
in differentiation of naïve CD4+ Th cells towards Th2 pattern (Keel & Trentz, 2004). 
IL - 12 is mainly produced by antigen-presenting cells such as macrophages and dendritic 
cells and exert a proliferative activity on NK cells and T cells, increasing the production of 
interferon-gamma from these cells, as shown in figure 15.  IL - 12 plays a critical role in 
differentiation of naïve CD4⁺ T cells towards T helper1 cells (Th1). This polarisation towards 
Th1 cells, results in further IFN-γ secretion which stimulates bactericidal effect of phagocytic 
cells and promote cell-mediated immunity (D’Andrea et al., 1992; Stern et al., 1996). All this 
makes IL - 12  an important link between innate and adaptive immunity. IFN-γ in turn 
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regulates the production of IL - 12 in a positive feedback-loop (Zundler & Neurath, 2015; 
Watford et al., 2013). 
            
Figure 14: Cellular basis of IL - 12 secretion. The figure shows IL - 12 production by antigen-presenting 
cells and phagocytic cells, and its action on T cells and NK cells, inducing differentiation towards Th1 
type cells, IFN-γ production and increased cytotoxic activity of T and NK cells (Watford et al., 2003). 
 
Grohman et al., proved in 1998 that IL - 12 is the most potent initiator of the immune 
response by directly acting on professional antigen presenting cells such as dendritic cells 
which express high-affinity IL - 12R on their surface. Both IL - 12 subunits, α and β chains are 
encoded separately on human chromosomes 3 and 5. However, to obtain a biologically 
active IL - 12, the co-expression of both unit cDNAs are necessary (Gubler et al., 1991). IL - 12 
may exist only as IL - 12 p40 which can be secreted in excess as free a monomer and can 
form homodimers p40₂, which was found to have role in directly recruiting macrophages; in 
the animal model IL - 12 p40 induces the expression of TNF - α (Ha et al., 1999; Jana et al., 
2003).  
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IL - 12 receptor (IL-12R) is made up of two receptor subunits, IL - 12β1 and IL - 12β2. A high 
affinity IL - 12 binding site needs the expression of both β1 and β2 subunits. 
IL - 12 p35 interacts with β2 subunit, whereas IL - 12 p40 interacts with β1 subunit. IL - 12 R 
subunits are expressed on T cells, NK-cells and DC cells. Upon high-affinity binding of IL - 12 
to both subunits of IL - 12R, receptor-associate Jak2 is activated, which in turn 
phosphorylates IL - 12R Tyk2 situated in intracellular domain. This leads further to the 
phosphorylation of signal transducer and activation of transcription 4 (STAT4) which show to 
have an important role in IL - 12 signalling. STAT4 forms homodimers that translocate to the 
nucleus and binds to the IFN-γ promoter, inducing IFN-γ gene transcription (Ma et al., 2015; 
Watford et al., 2003). IFN-γ is the main activator for macrophages resulting in the synthesis 
of IL - 12 and IL - 12R and promotes Th1 development. INF-γ is known to suppress the 
expression of IL - 4 through interferon regulatory factors (IRF1 and IRF2) which acts as 
transcription repressors by binding to IL - 4 promoter, thus inhibiting Th2 responses (Elser et 
al., 2002). 
1.3.3 Anti-inflammatory cytokines 
The anti-inflammatory cytokines play a role of immunoregulators, modulating the 
inflammatory effect of pro-inflammatory cytokines and regulating the immune response 
toward homeostasis. The most important anti-inflammatory cytokines are IL - 10, IL - 4, IL - 
1RA and IL - 1, to name a few. 
1.3.3.1 Interleukin - 4 (IL - 4) 
IL - 4 is a cytokine with molecular weight of 12-20 kDa. It was first known as B-cell 
stimulatory factor-1 for its ability to increase the expression of class-II major 
histocompatibility complex (MHC) on resting B cells and to stimulate the production of Ig G 
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and Ig E from B-cells (Paul & O’Hara, 1987). IL - 4 is mainly produced by Th2 lymphocytes, 
and by the mast cells (Figure.15), basophils and eosinophils. It has an important role in naïve 
CD4⁺ T lymphocytes differentiation towards Th2 cells and their proliferation and has an 
inhibitory effect on Th1 differentiation through IFN-γ downregulation (Ul-Haq, Naz & Mesaik, 
2016).  IL - 4 has an autocrine effect on Th2 cells which produce more IL - 4.  IL - 5, IL - 6 and 
IL - 10 are other types of cytokines secreted by the stimulated Th2 cells (Tato et al., 2006).  
IL - 4 together with tumour necrosis factor (TNF) increases endothelial cell adhesiveness to 
T- cells and their migration at the site of inflammation, and can mediate chronic 
inflammation (Thornhill et al., 1990). 
 
Figure 15: Biological activity of IL-4 (Njoku, 2010) 
 
IL - 4 in association with IL - 13, both generated by Th2 lymphocytes, are involved in an 
alternative macrophage activation which is responsible for tissue repair and homeostasis 
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(Gordon,2003). IL - 4 is involved in several allergic and immune disorders, such as allergic 
asthma and atopic dermatitis. Increased IL - 4 and IL - 4R expression has been detected in 
breast, bladder and prostate cancer which may suggest that IL - 4 can increase tumour cells  
resistance to apoptosis (Ul-Haq, Naz, & Mesaik, 2016).  
IL - 4 is a polyfunctional cytokine with receptors presenting on multiple types of cells. IL - 4 is 
produced mainly by Th2 cells and also by natural Killer cells (NK), basophils, mast cells and 
eosinophils (Paul, 2015). In recent years it was found that IL - 4 is also produced by T 
follicular cells (Tfh) as a major alternative source of IL - 4 (Sahoo et al., 2016). IL - 4 has an 
autocrine role, inducing naïve CD4+ Th cells to differentiate in Th2 cells (Noben-Trauth et al., 
2002). Research has shown that an increased release of IL - 4 may be involved in the 
development of ARDS and SIRS (Li et al., 2002). Moreover, IL - 4 was found to be associated 
with the mortality in patients with SIRS, with higher levels in infectious SIRS. The high levels 
of the cytokine are reported to be associated with genetic variations in IL - 4 gene (Torre et 
al., 2000). Gu et al., (2011) showed that polymorphisms in the IL - 4 promoter are associated 
with the increase in expression of IL - 4, which might be associated with increase 
susceptibility to develop sepsis in trauma patients. 
IL - 4 modulates macrophage activity by induction of inhibitory activity through increase in 
the expression of FcyRllb2, an inhibitory receptor on monocytes. These findings might help 
in taking a different approach in the treatment of chronic autoimmune diseases (Pricop et 
al., 2001). On the other hand, natural killer (NK) cells exposed to microenvironmental IL - 4 , 
have shown reduced cytolytic potential and generated dendritic cells which promote T-cell 
tolerance (Moretta et al., 2006). 
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IL- 4 receptors (IL-4R) consists of an IL - 4Rα chain which binds with high affinity to IL - 4, and 
IL - 4Rγ chains necessary for signalling pathway activation. The complex IL - 4Rα/IL - 4Rγ is 
expressed on many types of lymphocytes, such B-cells, T-cells and NK-cells, and on the 
endothelial cells. As figure 18 shows, upon ligand binding to IL - 4Rα with high affinity and 
the dimerization with gamma chain (γc), a signal transduction cascade initiates the activation 
of Jak1 and Jak3. It induces tyrosine phosphorylation on cytoplasmic tails of IL - 4Rα and γ-
chain, followed by tyrosine phosphorylation of STAT6. 
Phosphorylated STAT6 undergoes homodimerization, then translocate to the nucleus and 
stimulates gene expression (De Vries, Carballido & Aversa, 1999; Walford & Doherty, 2013). 
STAT 6 has an important role in T-cell survival and proliferation, Th2 differentiation and 
progression of allergic and immune disorders (Ul-Hak, Naz & Mesaik, 2016)                                                        
STAT6 induces expression of GATA3-Th2 specific transcription factor. GATA3 is known to 
downregulate IL - 12 expression which results in Th1 cytokine-INF-γ suppression, inhibiting 
Th1 responses, thereby, it intensifies Th2 immunity (Li-Weber & Krammer, 2003). 
1.3.3.2 Interleukin - 10 (IL - 10) 
Interleukin - 10 is a cytokine of approximatively 21 kDa with important immunoregulatory 
functions. Its primary role is to limit inflammatory responses to pathogens and to maintain 
immune homeostasis. 
IL - 10 is a cytokine with anti-inflammatory properties. It is expressed by Th2, T-reg and Th-
17 cells and by other cells of the immune system (dendritic cells, natural killer cells, 
macrophages and neutrophils), acting as a feedback regulator of diverse immune responses. 
IL - 10 inhibits the development of Th1 cells but also suppress Th2 cells and allergic 
responses (Saraiva, & O’Garra, 2010). IL - 10 is an important counter immune-regulator 
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during systemic inflammatory response syndrome, modulating exaggerated 
proinflammatory responses. IL - 10 is postulated to be the main driver for the compensatory 
anti-inflammatory response syndrome (Liu et al., 2017). 
IL - 10 can be expressed by pathogen-activated dendritic cells, macrophages and neutrophils, 
and by T and B-cells.  IL - 10 can also be expressed by other types of leukocytes such as 
eosinophils and mast cells.  (Saraiva & O’Garra, 2010). Initially it was thought that IL - 10 to 
be produced only by only Th2 cells and was named as cytokine synthesis inhibitory factor 
(CSIF) for its property to inhibit Th1 cytokines production such as INF-γ, IL - 2 and GM-CSF 
(Fiorentino et al., 1989). Further studies showed that IL - 10 is also expressed by other cells 
specific to innate immunity (Siewe et al., 2006). Another sub-class of T lymphocyte known as 
T regulatory (Treg) cells mediate suppression of immune responses through IL-10 secreted 
by T regulatory1 (Tr1) and acting directly on effector cells (Arce-Sillas et al., 2016; Saraiva et 
al., 2010). IL - 10 can also be secreted by B-cell subpopulations able to suppress 
inflammation through paracrine mechanisms. In an autocrine manner IL - 10 regulates the 
differentiation of activated IL - 10-secreting B-cells in IgM and IgG secreting cells (Heine et 
al., 2014). 
However, IL -10 can regulate either Th1 and Th2 responses by limiting T-cell activation and 
differentiation (Couper, Blount & Riley, 2008). IL - 10 inhibitory effects result in reduced 
secretion of pro-inflammatory cytokines (INF-γ, IL - 1, IL - 6, IL - 12, TNF, GM-CSF) and 
inhibition of production of chemokines (IL - 8 and IP-10) and prostaglandins (PG-E2) (Figure 
16). 
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Figure 16: IL-10 function in maintaining homeostasis (Cho et al., 2015) 
 
The inhibitory effect of IL - 10 exerted over monocytes results in downregulation of 
expression of MHC class II antigens on their surface, suppressing their capacity to function as 
APC for T-cells activation. 
 IL - 10 inhibits the maturation of DC and induces differentiation of immature DC into 
macrophages with reduced capacity of producing IL – 12. Therefore, IL - 10 can inhibit 
differentiation of naïve T-cells in Th1 cell type and favour the differentiation in Th2 cells 
(Moore et al., 2001) . IL - 10 has also an inhibitory effect through B cell class switching from 
IgE towards IgG4 which leads to T-cell anergy (Akdis et al., 1998). Furthermore, IL - 10 is 
shown to have an effect on the growth and differentiation of B-cells and mast cells (Cho et 
al., 2015). Although IL - 10 shows predominantly inhibitory immune activity, studies have 
revealed that IL - 10 in combination with IL - 2 can stimulate immune responses by inducing 
the proliferation and cytotoxic activity of CD8⁺T lymphocytes (Santin et al., 2000), and 
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natural killer (NK) cells. This stimulation leads to increased production of IFN-γ, TNF-α and 
granulocyte-macrophage colony-stimulating factor (Carson et al., 1995). 
IL - 10 exists  in the form of a homodimer connected by two disulphide bridges, which makes 
it biologically active. IL - 10 receptor (IL - 10R) is a tetramer which comprises two IL - 10R-
alpha and two IL - 10R-beta subunits.  
Upon IL - 10 homodimer binding to IL - 10R-alpha subunit, the phosphorylation of Jak1-IL-
10R-alpha takes place and is followed by Tyk2-IL-10Rbeta subunit phosphorylation. As figure 
20 shows, their kinases will further phosphorylate tyrosine residues on the cytoplasmic 
domain of IL - 10R-alpha, which serve as docking site for STAT3. This leads to 
phosphorylation and homodimerization, followed by translocation to the nucleus, where it 
stimulates gene expression (Verma et al., 2016).  IL - 10 is a potent suppressor for gene 
expression for pro-inflammatory cytokines such IFN-γ which activates STAT1; STAT3 
activated by IL - 10 opposes STAT1, downregulating IFN-γ expression (Hu et al, 2007) 
Macrophages and dendritic cells express high levels of IL - 10R on their surface, therefore IL - 
10 regulates pro-inflammatory activity and their production, by regulation of gene 
expression. It targets proteins encoding for pro-inflammatory cytokines, chemokines 
through TLR signalling and their suppression (Murray, 2006). 
Some of the pathogens have evolved to exploit IL - 10 pathway and to inhibit the expression 
of pro-inflammatory genes by activating STAT3, as IL - 10 does, resulting in macrophages 
inability to express IL - 12 and TNF necessary to suppress the parasite (Butcher et al., 2005). 
 
57 
 
1.4 METHODS FOR CYTOKINES DETECTION AND QUANTIFICATION 
Cytokines are small secreted proteins with a vital role in intracellular communication. They 
are used as biomarkers for various diseases and in monitoring the progress of diseases or the 
response to a treatment. The cytokines are released into the intracellular space in minute 
quantities which makes them unsuitable for traditional protein detection technique such as 
gel electrophoresis or mass spectrometry, therefore immunoassays are the techniques of 
choice for cytokines detection (Kupcova Skalnikova et al., 2017).  
 
Figure 17: Schematic representing underlying principles of immunoassays. A) The cytokine binds to 
capture antibody then the cytokine is detected with the help of a detection antibody conjugated with 
a fluorescent tag. B) The antigen is directly enzyme-labelled and get immobilized on the capture 
antibody (Kupcova Skalnikova et al., 2017). 
 
The most used techniques for cytokines detection are enzymes-linked immunosorbent 
assays (ELISA) (Figure 17), antibody arrays such as bead-based immunoassays or planar 
arrays. More recently new techniques based on microchip monochromatic strips were 
developed for rapid diagnoses to be used as point of care testing (POCT) (Man et al., 2014). 
Recently, scientists from University of Strathclyde have developed a biosensor device 
containing microelectrodes that can detect one of the most important markers of sepsis, 
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IL - 6. The device can be implanted and used on patients in intensive care for constant 
monitoring and deliver a bedside diagnosis in only two minutes instead of 72 hours as the 
current testing. The reduced cost of the device and the rapid diagnosis of sepsis can save 
many lives in the future (www.strath.ac.uk, 2019). 
1.4.1 Enzyme-linked immunosorbent assay (ELISA)         
The ELISA technique is a method developed in 1971 (Aydin, 2015) and is used in diagnostic 
or biomedical research to detect and quantify specific antigens. The technique uses antigen 
immobilized on the wall of a 96-well microtiter plate.  
                                                                                                                                                                                                                                        
Figure 18: The principles of ELISA assays; direct, indirect and sandwich assay are shown (Image from 
Thermo Fisher Scientific) 
 
The antibody specific to the antigen is added and binds to antigen, as shown in figure 18 for 
direct and indirect assays (Gan & Patel, 2013).             
In the direct assay, the primary antibody conjugated to an enzyme binds to the antigen 
which is directly attached on the well surface. The indirect assay has the same principle as 
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the direct method, with the difference that a secondary antibody conjugated to an enzyme 
or fluorophore specific for the detection of the primary antibody is added and form an 
antigen-antibody complex. The most common enzymes used in ELISA assay is alkaline 
phosphatase, horseradish peroxidase or biotin.   
Another type of ELISA assay known as capture or sandwich assay, has the wells coated in 
capture antibodies specific to the antigen of interest. The antigen binds to the antibody and 
is followed by washing steps. Further, antibodies tagged with enzymes specific to the 
antigen are added and will bind to them. Even though the methods show some differences, 
they all have in common the addition of a chromogenic substrate which will show a colour 
change or fluorescence in the presence of the antigens. The intensity of the colour or signal 
is directly proportional to the amount of antigen present. The signal is detected and 
measured with an ELISA reader (Aydin, 2015; Gan& Patel,2013). 
The sandwich ELISA assay was found to be more sensitive than other types of ELISA 
methods. Indirect ELISA is more sensitive than direct method, this is achieved through the 
presence of multiple epitopes on the primary antibody which binds to the secondary 
antibody resulting in a better signal amplification. The large variety of secondary antibodies 
gives a great advantage to indirect method, but the direct method is quicker and eliminates 
cross-reactivity of a secondary antibody. Ready to use cytokine analysis kits are available 
from various companies. ELISA is a sensitive and specific method, it is easy to use, low-cost 
and rapidly produce results, but it needs a large volume of analyte and can be time 
consuming (Gan & Patel, 2013). 
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1.4.2 Antibody arrays 
This method is similar to ELISA, but the capture antibodies are spotted on a nitrocellulose 
membrane or glass. The serum or other types of analyte is diluted and mixed with 
biotinylated antibodies and left to incubate. The cytokines of interest are immobilized on the 
membrane/glass slide by the capture antibody. The detection step is performed with the aid 
of streptavidin-horseradish peroxidase and chemiluminescent reagents. In the case of 
membrane, the detection process does not need specialized equipment for detection 
resembling to western blot, whereas for glass slides, an array scanner is needed for 
detection and quantification of proteins of interest (Kupcova Skalnikova et al., 2017). 
1.4.3 Bead-Based immunoassays using flow cytometry 
The assay uses a flow cytometer, an instrument that can detect fluorescent signals from 
individual cells which flow in the front of a narrow beam of light. Modern flowcytometers, 
though using the same principle, can detect other types of particles besides whole cells,  
such as nuclei, cytokines and hormones, to name a few  (Givan, 2011). Curently, the flow 
cytometer measures optical and fluorescent characteristics of particles, such as light 
scattering and fluorescent emission from moving particles in the front of a laser beam. 
Physical characteristics measured are size, granularity, and fluorescence resulting from 
antibodies and dyes which are employed to identify and differentiate the particles of 
interest (Adan et al., 2017). 
The main components of a flow cytometer are the fluidics and optic systems for signal 
detection and measurements. Through the fluidic system the analyte is transported to the 
optical system. The fluidic system is comprised of sheath fluid and the analyte in form of 
solution which is injected in the flow chamber at a high pressure. According to 
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hydrodynamic focusing principles, the particles will align in a single line while passing 
through the interrogation point, where the cell meet with the laser beam. (Figure 19). The 
optical system is made up of lasers and lenses with  arole in focusing the laser beam on to 
the cell. The light scattered by cells divides in forward scatter (FSC) in a manner proportional 
to the size of the cell or particles, and side scatter (SSC), related to cell granularity or internal 
complexity, and also detects fluorescent-labelled antibodies or dyes (Givan, 2010). 
  
Figure 19:  The principles of flow cytometry; the fluid flows in the front of a laser beam where optical 
and fluorescent characteristics of particles are measured. The light is deflected in contact with the 
cells  resulting in forward scatter (FSC) and side scatter (SSC). The signals are then converted in 
voltages by photodetectors (PMT), then converted in digital data displayed on a computer  (Adan et 
al., 2017) 
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The detection of the emitted fluorescent light is done with the aid of a series of dichroic 
mirrors and filters, which transmits and reflects the light of specific wavelengths onto 
photomultiplier tubes (PMT). PMTs are vacuum tubes containing a photocathode, electron 
focusing electrodes and dyodes for electron multiplication. Further, the voltage pulse 
created is amplified and digitized, then all the data collected is summarized in a distribution 
curve or a histogram (Cossarrizza et al., 2017). 
Flow cytometric techiques can use surface and intracelluar markers to track the progression 
of cellular activity. It can also observe cellular events by using specific florophore-labeled 
antibodies to identify cell transition from one stage to another. Flow cytometry is also used 
for characterisation of intracellular epitopes, such as hormone receptors, cell cycle proteins, 
enzymes, DNA and mRNA. Flow cytometry has the advantage that it can measure 
simultaneously surface antigens and intracellulat antigens, analyze B cells vs T cells, or 
diseased cells against healthy cells, all in the same experiment( Krutzik et al., 2004).  
Flow cytometric methods are also used to detect cytokine production, such as antigen-
specific T-cells responses to proteins, viral lysate or peptide, and detect simultaneously CD4 
and CD8 T-cells from the same sample used for stimulation (Maino & Maecker, 2004). 
For decades, researchers in cell biology and immunology were interested in measurement of 
soluble mediators involved in immune regulation. ELISA methods are already used for 
measurements of soluble analyte analysis but has some limitations , such as labor-intensive 
at high cost, but it measures only one analyte at a time using an incresed volume of sample 
(Klein et al., 2012). As biomedical research became more complex, the necessity to improve 
the old methods increased, therefore, new methods such bead-based flow cytometric 
immunoassays were developed. Some techniques employ beads of different sizes or colours 
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as carriers for antigens and antibodies (McHugh, 1994). Others use beads coated with more 
than one antibody carrying different fluorochromes, each being able to detect specific 
antigens (Collins et al., 1998).  
Bead-based flow cytometric immunoassays facilitate simultaneous measurement of multiple 
analytes in small volumes of biological fluids. With this methodology, one single sample can 
be analysed for inflammatory mediators and their receptors such as cytokines, chemokines 
and  immunoglobulins, during a single test (Varro et al., 2007). The multiplex analysis is 
possible  due to distinct high fluorescence intensity microspheres with different scatter 
characteristics, which differentiate them from other microspheres specific for other analyte. 
Each type of beads are conjugated with a specific high affinity antibody directed against a 
particular molecule from serum, cell culture or cell lysate.  
 
Figure 20: The principle underlying bead-based flow cytometric immune assays (BD Bioscience) 
As figure 20 shows, detection antibodies are added to sandwich the complex of capture 
beads and the analyte, and mediate the detection of fluorescent signal, which is 
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proportional to the concentration of the analyte. The concentration for each analyte is then 
determined against standard curves using specific software provided by companies 
producing cytometric bead assays (Morgan et al., 2004; Varro et al., 2007). 
The bead-based assay provides simplicity by eliminating some of washing steps without 
losing in specificity. The method is reliable and reproducible due to standardisation between 
assays provided by standard calibration beads. This ensures that tests performed in different 
places at different times can offer comparable results. Furthermore, due to the increased 
surface area of microspheres, the test requires a reduced volume of the sample, compared 
to ELISA methods. The method also offers simultaneous analysis of several analytes and 
time-efficiency but can be prohibitive for some institution or researchers due to high cost of 
the instruments (Young et al., 2008).   
1.5 CLINICAL OUTCOME AS A RESPONSE TO TRAUMATIC INJURY 
Tissue injury resulting from accidents or violence instigate immunologic and metabolic 
responses with a role in restoring the homeostasis. in the worst scenario, traumatic injury 
may result in metabolic, immunologic and physiological changes, correlated with the 
magnitude of the tissue injury. These changes lead to organ failure or coagulopathies and 
can trigger an overexuberant inflammatory process, and all together may lead to death (Keel 
& Trenz,2004). 
Muir (2006), describes how trauma follows a trimodal distribution, comprised of an 
immediate death due to devastating trauma with over 30 % loss in total blood volume or 
due to brain injury. The next are the early deaths which occur between 2 and 24 hours from 
admission to hospital and associated with hypoxia due to ongoing haemorrhage, or due to 
cardiovascular or respiratory system deficiency. Seriously injured patients who survive these 
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two steps, risk to develop immunological dysfunctions leading to complications. The third 
category is defined by late deaths which happen days or weeks after the traumatic event 
and are consequent to cardiorespiratory failure, acid-base imbalance, systemic inflammatory 
response syndrome (SIRS), adult respiratory distress syndrome (ARDS) and multiple organ 
failure (MOF).  
Soon after a massive traumatic injury, a vigorous pro-inflammatory response with increase in 
serum levels of cytokines takes place, with a role in mounting a response to the trauma, in 
the form of SIRS. The most important cytokines secreted in the beginning of the pro-
inflammatory state are IL - 1, IL - 6, IL - 12, TNF-α and IFN-γ. They act as acute phase 
hormones or danger signals, with a role in secretion of C-reactive protein and procalcitonin. 
The more severe the injury, the higher the levels of these cytokines are, and correlate to 
injury severity scores (ISS) (Lenz et al., 2007).   
A two-hit model was proposed in the late 1990s which states that the first traumatic event 
named the first hit, represents the priming event for a secondary event related to the 
traumatic injury. The secondary event results during the hospital stay as a response to 
reparatory surgical intervention, fluid replacement or nosocomial infections. It is considered 
that the priming event can drive the patient towards developing SIRS, and the second hit can 
lead to multiple organ failure and later to death (Morris et al., 2015). 
The pro-inflammatory status is dampened down by anti-inflammatory mediators in a 
mechanism known as the counter inflammatory response. It runs parallel to the 
inflammation, opposing it in a balanced manner leading to healing and achieving 
homeostasis (Figure 21).  
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However, an unbalanced counter inflammatory response can lead to compensatory anti-
inflammatory response syndrome (CARS) with the anti-inflammatory dominant state 
responsible for post-traumatic immunosuppression due to T-cells disfunction. This process 
leaves the patient vulnerable to opportunistic infections, sepsis, and in some cases can lead 
to multiple organ failure and death (Zedler & Faist, 2006; Morris et al., 2015). 
          
Figure 21: The model of injury for systemic inflammatory response syndrome (SIRS), compensatory 
anti-inflammatory response syndrome (CARS) (Choileain & Redmond, 2006) 
 
Researches are showing that observing the inflammatory status provided by modulation of 
cytokine release before reparatory surgery, can help to avoid the development of SIRS, MOF, 
sepsis and also to reduce mortality in trauma patients (Harwood et al., 2005; Moghtadaei et 
al., 2016). 
1.5.1 Systemic inflammatory response syndrome (SIRS) 
SIRS is a result of a generalized aberrant inflammatory response in organs remote to the 
initial insult. SIRS can be associated to non-infectious(sterile) sources such as trauma, burns 
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or major surgery; when the process is associated to infection, SIRS  is defined as sepsis (Bone 
et al., 1992). SIRS can be recognized following the observation on several clinical criteria, 
showed in table 1.  When the patient presents two or more of the presented criteria, then 
there is a high possibility that the patient will develop SIRS (Martin &Badeaux, 2016). 
Table 1: Parameters used as guide to determine the presence of systemic inflammatory response 
syndrome (Martin& Badeaux,2016). 
SYSTEMIC INFLAMMATORY RESPONSE SYNDROM 
• Temperature >38 ◦C or < 36◦C 
• Heart rate > 90 beats/min 
• Respiratory rate >20/min or PaCO2 < 32 mmHg (4.3kPa) 
• White blood cell count >12,000/mm3 or <4000/m3 or >10% immature bands 
 
The activation of the immune cells and secretion of cytokines have a role in achieving 
homeostasis, wound healing and tissue repair, being regulated by anti-inflammatory 
mediators. SIRS is driven by the strong systemic release of pro-inflammatory mediators from 
activated immune cells together with anti-inflammatory mediators. Its incapacity to restore 
the host’s homeostasis leads to a dysregulated immune response and immune paralysis.  
In the presence of disrupted cellular membranes or other danger signals released by injured 
cells, a series of mediators are released from immune cells in the area where the traumatic 
injury took place. Histamines, bradykinins and chemokines are released to act upon 
endothelium to facilitate the migration of neutrophils and monocytes towards the damaged 
site to restore tissue integrity. In severe trauma, a spill-over of inflammatory mediators in 
the peripheral blood stream increases the systemic inflammatory response. Furthermore, 
systemic activation of polymorphonuclear cells (PMC) leads to their sequestration in organs 
which were not affected by the initial insult (Lenz et al, 2007). One example is about primed 
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neutrophils sequestrated in tissues and organs such as liver or lung; they are responsible for 
liver failure, pulmonary failure and acute respiratory distress syndrome (ARDS) (Bhatia et al., 
2005). 
Polymorphonuclear cells have an important role in phagocytosis and killing of invading 
pathogens (Pechous, 2017), but at the same time they can damage the surrounding tissues 
through degranulation of elastase and metalloproteinases. Elastases degrade proteins in 
extracellular matrix and plasma proteins, whereas metalloproteinases are involved in 
destruction of structural proteins. In addition, the release of reactive oxygen species (ROS), 
hydrogen peroxide (H2O2), or other immune mediators, can lead to more damage added to 
the already damaged tissue or to death (Hu et al., 2017). ROS, H2O2 and hydroxyl radicals  
generated from infection and inflammation are the major cause of DNA damage, double 
strand DNA breaks, DNA-protein cross-links, leading to mutations and cell death (Ragu et al., 
2007). Reactive nitrogen species (RNS) such as nitric oxide (NO) are also involved in tissue 
damage and vascular dysfunction (Keel& Trentz,2005).  
There is a well-orchestrated interplay between multiple mediators as response to traumatic 
injury. During SIRS, the most important mediator is TNF-α, which is the most potent cytokine 
with role in coagulation, release of adhesion molecules and other molecules specific to early 
stages of traumatic injury. It also induces the secretion of other cytokines like IL - 6 and IL - 
1β. TNF- α and IL - 1β were shown to be associated with the development of MODS, ARDS or 
sepsis. IL - 6 and the chemokine IL - 8 levels are found to be increased during the initial 
phase of traumatic injury. Moreover, increased levels of IL - 8 has been shown to be 
correlated with mortality from ARDS (Reikeras, 2010). Monocytes and macrophages are 
further involved in differentiation of T-helper lymphocytes. They produce IL - 12 which drives 
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the differentiation of Th cells in Th1 type cells which secrete IL - 2, IFN-γ and support the 
inflammation. Decrease in production of IL - 12 from macrophages leads to a shift towards 
Th2 lymphocytes which support the anti-inflammatory state (Keel & Trenz, 2005). 
1.5.2 Compensatory anti-inflammatory response syndrome (CARS) 
Parallel to the state of inflammation, many anti-inflammatory mediators are produced with 
a role to dampen down the inflammation. However, an overproduction of anti-inflammatory 
mediators may lead to a hypo-inflammatory phase. Macrophages and Th2 lymphocytes are 
responsible for the production of anti-inflammatory cytokines, such as IL - 4, IL - 10, IL - 13 
and TGF-β. A contribution to anti-inflammation is provided by IL - 6  and also by cytokine 
receptor-antagonists, such as IL - 1Ra and TNFRI. IL - 10, however, is reported to be the most 
important anti-inflammatory agent in terms of suppressing the transcription of pro-
inflammatory cytokines (Schroder et al., 2004). A cohort of patients which surviving the SIRS 
response are affected by a lengthy dangerous, state known as compensatory anti-
inflammatory response syndrome (CARS). It is characterised by T-cells hypo-responsiveness 
and suppression of their proliferation, defects in antigen presentation and T-cell apoptosis. A 
hypothesis for these events was associated to IL-10 promoter polymorphism and its link to 
multiple organ dysfunction syndrome (MODS) (Gentile et al., 2012; Schroder et al., 2004).  
The state of CARS leaves the patient in a profound immunosuppression allowing 
opportunistic infections to take over and resulting in septic complications. The 
immunosuppression process and ongoing inflammation consume energy derived from fat 
and protein catabolism, which results in loss of body mass, poor wound healing and 
recurrent infection. However, the immune system is very fine tuned and shows a very good 
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equilibrium between SIRS and CARS trying to avoid an overwhelming inflammation directed 
to its own self, and also to limit the access of infectious agents (Keel & Trentz, 2005).  
1.6 CONSEQUENCES OF THE IMBALANCE BETWEEN SIRS AND CARS  
Pro-inflammation (SIRS) and anti-inflammation (CARS) coexist from the beginning of the 
traumatic injury. The intensity and the balance of these two events can result in either a 
physiologic resolution or in organ dysfunction. If the traumatic event is followed by severe 
SIRS, the excessive pro-inflammation can cause early organ disfunction, while an early anti-
inflammation inhibits pro-inflammatory mediators which may lead to immune-paralysis and 
susceptibility to nosocomial infections.  
In a major injury the inflammatory response can become systemic and lead to serious 
consequences, including acute respiratory distress syndrome (ARDS) and multiple organ 
failure (MOF) 
1.6.1 Acute respiratory distress syndrome (ARDS) 
ARDS was first described in 1967 as an acute inflammatory lung injury, characterised by 
increased lung microvascular permeability with accumulation of protein-rich fluid, 
concluding in hypoxemic respiratory failure and poor lung compliance. It presents with 
dyspnoea and requires assisted ventilation. Statistics show that nearly 40% of patients with 
ARDS die, whereas survivors are left with lifelong consequences (Laffey, Misak & Kavanagh, 
2017). Sepsis is the leading risk factor for ARDS and presents a higher rate of mortality, 
compared to only 7% trauma-associated ARDS with a mortality rate of 24% (XU & Song, 
2017).  
The American-European Consensus Conference (AECC) characterises ARDS through three 
diagnostic criteria: 
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• Presence of acute hypoxaemia: (PaO2/FiO2) >200 mmHg (26.7 kPa) and <300 mm Hg 
(40kPa) 
• Bilateral infiltrates on chest radiography (CXR) 
• Absence of raised pulmonary artery pressure < 18 mm Hg or no clinical evidence of 
left atrial hypertension 
While the definition presents limitations from the point of view of reproducibility, lack of 
sensitivity and specificity, but nevertheless, those 3 criteria help to identify the onset of 
ARDS (Dushianthan et al., 2011). 
The pathogenesis of ARDS shows a progressive, uncontrolled lung inflammation with 
accumulation of neutrophils, macrophages and erythrocytes in the alveolar space and 
hyaline membrane formation. ARDS is divided in three stages: exudative, proliferative and 
fibrotic. The first phase is characterised by increased lung microvascular permeability, 
leakage of proteinaceous fluid and leukocytes migration in the alveoli (Figure 26). The 
leukocytes release inflammatory mediators, such as ICAM-1, selectins and VEGF which 
disrupt the bonds of VE-cadherin (an adherens junction protein). It destabilizes the lung 
microvascular barrier function (Matthay et al., 2012), and are responsible for leukocytes 
accumulation and transmigration (Calfee et al., 2007). The second stage, 7-14 days after 
injury is characterised by proliferation of fibroblasts and Type II pneumocytes which attempt 
to replace necrotic alveolar Type I cells. The fibroblasts release extracellular matrix proteins 
and migrate into alveolar space, attaching to the denudated basement membrane. Some 
patients will progress to the third stage characterised by intra-alveolar fibrosis with 
deposition of alveolar collagen, which characterise the fibrotic stage (Fig 22).  
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Extended fibrosis reduces lung compliance with decreased tidal volume and CO2 retention, 
poor gas exchange which contributes to hypoxia and ventilator dependence (Bellingan, 
2002). 
         
        Figure 22: Acute phase alveolar injury (Calfee et al., 2007) 
 
The inflammatory process is driven by TNF - α, IL - 1, IL - 6 and IL - 8. They promote 
neutrophil-endothelium adhesion and microvascular leakage. Neutrophil traps and histones, 
proteases and oxidants released by neutrophils contribute to endothelial and alveolar injury.  
TNF - α, IL - 1β and TGF-α have an important role in development of lung fibrosis. On the 
other hand, anti-inflammatory mediators IL - 4, IL - 10, IL - 1Ra, and low concentration of CO 
(carbon monoxide) have proven anti-inflammatory effect in ARDS (Bellingan, 2002). New 
therapies try to stabilize the lung and endothelial barriers targeting VE-cadherin bonds 
through administration of stabilizing ligands with role in cytoskeletal reorganization. VE-
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cadherin is critical for the maintenance of endothelial barrier integrity in lung micro-vessels. 
Disruption of VE-cadherin bonds was shown to be associated with accumulation of 
leukocytes and platelets in micro-vessels proving the close relationship between barrier 
integrity and leukocyte transmigration. Restoring the barrier integrity using mesenchymal 
stem cells can help to reverse the major disfunctions associated with lung injury and ARDS 
(Matthay et al., 2012). 
1.6.2 Multiple organ dysfunction syndrome (MODS) and multiple organ failure (MOF) 
Multiple organ dysfunction syndrome is the result of a life-threatening injury, which 
develops in a potentially reversible dysfunction involving two or more organs, not involved 
in the initial injury (Marshall,2001). The organs taken into consideration are respiratory, 
cardiovascular, neurological, renal, hepatic, and haematologic systems. MODS is associated 
with irreversible organ damage and has a high rate of mortality resulting from hypovolemic 
shock, ischemia reperfusion injury, extensive injury, and an imbalanced immune system 
response (Barie et al., 2008). MODS is generally a consequence of sepsis but can also result 
from traumatic injuries and secondary to SIRS (Osterbur et al., 2014). 
Due to improvements in trauma care, the incidence of MODS has decreased in the last 
decades but is still present in about 13-33 % of cases of traumatic incidents. Forty-four to 76 
% of ICU patients with MODS may result in late deaths (Ostebur et al., 2014; van Wessem et 
Leenen, 2017). Researches show that age and highly traumatic injuries with prolonged 
hospital stay are factors that predispose to developing of MODS with increased of death ( 
Barie et al., 2008; Ciesla, 2005). 
The pathogenesis of MODS is still not well elucidated. Some described that the developing of 
MODS is due to excessive inflammation and to a dysregulated immune response or immune-
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paralysis, others describe it as a result of the second-hit insult. MODS can be classified as a 
primary MODS when the organ dysfunction results directly from the primary insult, and 
secondary MODS when the organ dysfunction was resulted from systemic response 
developed in a distant organ different from the initial injury (Osterbur, 2014). However, the 
first minutes to hours show to be cardinal for the development of a normal or a 
dysregulated immune response and influence the development of MODS.  
Table 2: Multiple organ dysfunction score (Marshal, 2001) 
 
(Abbreviations: PO2- partial oxygen pressure; FIO2 – fraction of inspired oxygen; Units : serum 
creatinine –  µmole/l; serum bilirubin- µmole/l; platelet count –platelets/mL 10⁻ᶾ ) 
 
When organ dysfunction leads to failure of two or more organs it means that the MODS has 
developed into multiple organ failure (MOF). A classification of MOF distinguishes the early 
MOF characterised of multiorgan failure developed in the first 72 hours from injury, from the 
late MOF which develops three day away from the traumatic injury and represent 
approximatively 60% of total MOF (Llompart-Pou et al., 2014).  
MOF is a consequence of SIRS, ischemia-reperfusion and haemorrhagic shock (Figure 23). 
The respiratory failure is present in 99% of all cases, showing that the lung plays a key role in 
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development of early MOF. The next organ to be affected is the heart, just few hours after 
respiratory failure, followed by liver and kidney dysfunction up to 5 days after the injury 
(Llompart-Pou et al., 2014). Eighty-seven per cent of single-organ failure is represented by 
lung dysfunctions, whereas in patients with 2 or more organ dysfunction 99% had lung 
dysfunction. These data suggest that lung dysfunction is a key component in development of 
post injury MOF, with the lung being a source of inflammatory cytokines and their systemic 
release (Suter et al., 1991; Ciesla et al., 2005).   
                  
 
Figure 23: The pathophysiology of MOF following severe traumatic injury (Llompart-Pou et al., 2014) 
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A well-balanced immune system ensures the achievement of homeostasis after a traumatic 
event. Pro-inflammatory cytokines IL - 1β, IL - 6, IL - 8 and TNF-α are produced in excess after 
traumatic injury and together with acute phase proteins contribute to host defence and 
perpetuate local and systemic inflammatory response (Llompart-Pou et al., 2014). IL - 6 is a 
good indicator of trauma severity and outcome, whereas IL - 8 concentration is correlated to 
the development of ARDS. The complement system activation takes place at the site of 
injury with role in clearance of pathogens and act as a chemoattractant for phagocytes and 
other PMN cells towards the site of injury. Plasma protein complement C3 levels is also a 
hallmark for the outcome of traumatic injury (Charlie-Silva et al.,2019; Hecke et al., 1997). 
IL - 8 has an important role in attracting the neutrophils at the site of damage, exerting their 
role in defence and phagocytosis of debris at the site of injury. Together with TNF-α and 
complement C5a contributes to the development of systemic inflammatory response 
syndrome and MOF. The ischemia-reperfusion characterised by temporary deprivation of 
blood supply and restoration of blood flow, plays an important part in development of MOF. 
The reperfusion phase is responsible for the formation of free radicals, such hydrogen 
peroxide (H₂O₂) and hydroxyl ions, leading to apoptosis and cell necrosis and predispose to 
multiple organ failure (Cryer, 2000). 
As shown before, severe trauma causes systemic inflammatory response syndrome (SIRS) 
which can lead to multi organ failure (MOF) in absence of source of infection. Moreover, 
researches have shown that expression of innate immunity genes responsible for SIRS are 
expressed simultaneously with expression of genes responsible for counter-inflammatory 
response syndrome (CARS) (Xiao et al., 2011). 
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 While in-hospital, mortality due to traumatic injury has decreased thanks to the 
introduction of the “Trauma system” (Leckey, 2018), and a new phenotype of late MOF 
developed. The patients belonging to this category remain critically ill in the ICU; they 
present with persistent inflammation, immunosuppression and catabolism syndrome (PICS) 
(Shepherd, Cole & Brohi, 2017; Vanzant et al., 2014). They exhibit persistent low-grade 
inflammation with IL - 6 and IL - 8 still elevated levels and increased white blood cell counts 
(WBC). Concomitant immunosuppression with elevated IL-10 and lymphopenia is associated 
with decreased HLA-DR on CD14+ monocytes. Genomic analysis shows that up-regulated 
pathways for IL - 10 and IL - 6 were associated with complicated recovery (Xiao et al., 2011). 
Patients in this category also present low albumin levels and lean muscle wasting with high 
levels of 3-methylhistidine to creatinine ratio, showing protein catabolism (Horiguchi et al., 
2018). Patients affected with PICS fail to recover and are prone to infection and they will be 
further transferred to long-term acute care facilities (Vanzant et al., 2014). 
1.6.2 Sepsis 
The third international consensus definition for sepsis and septic shock revised the definition 
of sepsis as ‘a life-threatening organ dysfunction caused by dysregulated host response to 
infection ‘(Singer et al, 2016). Clinical findings in sepsis diagnosis are the presence of an 
infectious agent and a sequential organ failure assessment (SOFA) score ≥ 2 (Table 3). The 
patients with SOFA score ≥ 2 have an in-hospital rate of mortality > 10% compared with 
patients with SOFA score < 2 (Keeley, Hine & Nsutebu, 2016). Sepsis represents a major 
public health problem as its incidence is increasing due to aging population who present 
with multiple comorbidities or are under immunosuppressive therapies. Sepsis claims every 
year, approximately 5 million death worldwide (Brent, 2017).  
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Table 3: Parameters that defines sepsis (Brent, 2017) 
Respiratory rate >22/ minute 
Altered mentation status 
Systolic blood pressure < 100mgHg 
SOFA score ≥ 2  
 
Systemic inflammatory response syndrome (SIRS), is a consequence of a spill-over of 
immune mediators from a localised inflammation into systemic circulation. The cause of 
inflammation can be due to an infectious agent such as bacteria , fungi or viruses, and can 
also be caused by non-infectious causes such as traumatic injuries, therefore, sepsis is an 
extreme response to inflammation. 
There are many theories regarding sepsis, one theory supports the idea that there is an 
initial pro-inflammatory stage dominate by SIRS followed by an anti-inflammatory stage 
CARS. This leave the patient immunocompromised and predisposed to new infections 
leading to MOF (Hotchkiss &Karl, 2003). Newer studies find that there is a simultaneous 
activation of pro-inflammation and anti -inflammatory processes (Greenhalgh, 2017). Studies 
based on genetic analysis showed that traumatic injury resulted in SIRS might be caused by 
polymorphism in genes responsible for cytokines production (Zhang et al., 2015; Kingsley & 
Bhat, 2017) which can result in a persistent hyper-inflammatory state. However, other 
groups of researchers have found that immunosuppression is the cause of sepsis (Broomer 
et al., 2011; Hotchkiss et al., 2013). Moreover, trauma patients undergoing orthopaedic 
surgery are shown to develop post-operative septic complications at a rate of 1.6% higher 
when compared with non-trauma cohort (Lakomkin et al., 2017). 
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1.7 SCORING SYSTEMS IN TRAUMA 
Trauma is the leading cause for mortality and morbidity in the developed world. In order to 
understand the magnitude of traumatic injury and the methods of treatment, scoring system 
are in place to assess the severity of injury and stratify patients in order to identify seriously 
injured patients and trigger a trauma team with an adequate treatment (Kingston & 
O’Flanagan, 2000). There are more types of trauma scoring systems available to assess 
traumatic injuries.  
1.7.1 Injury severity score (ISS) 
ISS is an anatomical scoring which observes an accurate description of the injury and is 
considered the “gold standard “score (Deng et al., 2016). ISS is calculated as a sum of the 
squares of the single highest abbreviated injury scale (AIS) score for each of the three most 
severely injured body regions, with one injury per body part taken in consideration (Deng et 
al., 2016; TARN). 
Table 4: Abbreviated injury scale(Palmer & al., 2016)  
AIS value Injury description 
0 No injury 
1 Minor 
2 Moderate 
3 Serious 
4 Severe 
5 Critical 
6 Un-survivable 
 
The Abbreviated injury scale (Table 3) is an important tool for grading the severity of injury 
for trauma patients, with ‘0’ for no injury to ‘6’ for fatal injury (Kingston & O’Flanagan, 2000). 
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To calculate ISS the body is divided in 6 areas of the body: head and neck, face, thorax, 
abdomen and viscera, limbs and bony pelvis, and body surface. The sum of squares of three 
of the highest AIS scoring represent the ISS and can vary from 0 to 75 for un-survivable 
injuries (TARN.AC.UK). A cut off for ISS ≥ 16 was internationally accepted for severely 
traumatised patients which is associated with a mortality rate above 10% (Maduz et al., 
2017; Palmer et al., 2016). Some of the information necessary to calculate ISS might be 
difficult to obtain in acute stages or only obtainable using CT scan. However, it is 
considered., as time-consuming scoring and incompatible with acute setting, resulting in 
data collection to be completed for only about 25% of cases (Kingston & O’Flanagan, 2000).   
1.7.2 Glasgow coma scale (GCS) 
GCS is part of a physiological scoring system which observes and measures vital signs to 
determine the level of physiological derangements caused by injury (Kingston & O’Flanagan, 
2000).  GCS was introduced in 1974 to assess the level of consciousness following head 
injury. It observes three aspects of responsiveness: eye-opening, motor, and verbal 
responsiveness.  
The levels of response in all three components are scored from ‘1’ for no response to ‘4’ for 
normal values (eye-opening response), ‘5’ (verbal response) and ‘6’ (motor response). GCS 
score has cumulate values from ‘3’ which means-no eye opening, no verbal response, no 
motor response, representing the worst score, and ‘15’ which is the highest score for no 
head injury (Jain, Teasdale & Iverson, 2019) (Table 5). GCS is incorporated in clinical decision 
for management of the patients with brain injury, such as in a case of a patient with GCS 
equal to ‘8’ or less which will require endotracheal intubation (Sternbach,2000). 
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Table 5: Glasgow coma scale (Jain, Teasdale & Iverson, 2019) 
Feature Scale 
Response 
Score 
Eye opening Spontaneous 
To speech 
To pain 
None 
4 
3 
2 
1 
Verbal response Oriented 
Confused conversation 
Words(inappropriate) 
Sounds (Incomprehensible) 
None 
5 
4 
3 
2 
1 
Best motor response Obey commands 
Localise pain 
Flexion-normal 
             -abnormal 
Extend 
None 
6 
5 
4 
3 
2 
1 
 
GCS has the advantage that it can rapidly and continually assess the patient’s state and 
outcome and help to observe eventual improvements or deterioration. GCS was found to 
have good predictive values for hospital mortality (Gmec & Gasparovic, 2000; Asensio & 
Tunkey, 2015). 
1.7.3 Sequential organ failure assessment (SOFA) 
The sequential organ failure scoring system was introduced in 1994 to monitor the 
assessment of organ dysfunction or failure over time, and/or evaluate the patient’s response 
to a treatment during the organ dysfunction (Llompart-Pou et al., 2014). SOFA score is not 
designated to predict an outcome, but to describe a sequence of complications in critically ill 
patients. SOFA calculates the sum values for the degree of dysfunction in six organs (Table 
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6.) The score ranges from ‘0’ (normal) to ‘4’ (most abnormal) for each organ. The higher the 
SOFA score, the highest the mortality rate was shown (Vincent et al., 1996). A SOFA score of 
3 or greater for one organ systems is considered a failure of that organ.  
Table 6: SOFA score (Llompart-Pou et al., 2014) 
 
Compared with other used scoring systems, SOFA score is considered to have the most 
balanced relation of sensitivity and specificity (Frohlich et al., 2016). The six systems taken in 
consideration for calculation of SOFA score are respiratory, coagulation, liver, cardiovascular, 
kidney and CNS. 
While the SOFA score on admission could be used to stratify patients presenting in 
emergency departments, the late phase outcomes may not necessarily be predictive in 
major trauma patients with second phase complications. It is however a useful metric to 
monitor the onset of the second phase complications. The patients presenting with higher 
SOFA score need more urgent attention as organ dysfunction is associated with higher 
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mortality rates (Hu et al., 2017). This scoring system is easy to use and could provide 
valuable information which could be used as a proxy measure of poor clinical outcome. 
Early identification of patients at risk of developing sepsis is crucial in order to receive 
focussed, early clinical interventions. A SOFA score higher than 3 describes organ failure 
(Antonelli et al., 1999; Fueglistaler et al., 2010) whereas SOFA ≥ 6 results in an increase in 
mortality rate of more than 25% (Lie et al., 2018; Shabir & Maqbool, 2017). Therefore, a cut-
off of 3 and one of 6 for SOFA score were used for data analysis in the thesis. 
SOFA score is considered to be a measure of multiple organ dysfunction resulting from SIRS 
and sepsis and is a reliable (albeit late) indicator of critically ill patients in an ICU setting. 
SOFA score of 0 means the patient does not present any organ failure (Raith et al., 2017), 
SOFA score represents cumulative organ dysfunction experienced by the patient with 
traumatic injuries. With the increase in SOFA score value, increases the number of organs 
failing to function during the hospital stay. Being able to predict from early stages the 
evolution of SOFA score can facilitate early diagnosis and support for failing organs and also 
to decrease the mortality rate (Ferreira et al, 2001). SOFA score ≥ 6 was found to be 
correlated with higher mortality (Lie et al., 2018; Keelley et al., 2016).whereas SOFA ≥ 3 is 
correlated to organ failure (Moreno et al., 1999; Keelley et al., 2016). 
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1.8 Aim of the study 
The main aim of the study is to identify trends in IL - 4, IL - 6, IL - 10 and IL - 12 cytokines, 
with a view to identifying potential biomarkers for predicting poor clinical outcome in major 
trauma patients (n =80) admitted to Central Manchester Foundation Trust (CMFT) and 
Salford Royal Foundation Trust (SRFT). This will be accomplished through the following 
objectives: 
• Recruitment and sampling of 80 patients admitted with major trauma to CMFT and 
SRFT.  
• Analysis of serum samples obtained from Day 1, 3 and 5 post admission for cytokines 
IL - 4, IL - 6, IL - 10 and IL – 12 using optimised cytometric bead arrays and 
flowcytometry. 
• Collation of associated clinical meta data from patients on Day 1, 3, 5 and 8 and the 
calculation of progressive SOFA scores as a proxy of multiple organ dysfunction and 
poor clinical outcome. 
• Data analysis to establish cytokine trends on major trauma patients. Correlation of 
cytokine data to indices of poor clinical outcome (SOFA, creatinine, lactate, mortality 
etc.) to identify early (D1) cytokine profiles which could be used as predictors 
(potential biomarkers) of late, poor clinical outcomes.   
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CHAPTER 2- STUDY DESIGN, METHODS AND MATERIALS 
2.1 STUDY DESIGN AND ETHICAL CONSIDERATIONS 
The research project was designed to find correlations/associations between immune 
biomarkers and clinical outcome following traumatic injury in a large group of patients 
(n=80). The study was granted UKCRN-NIHR Portfolio status (BIT 19377), which supported 
research nurse funding for clinical activities in Central Manchester Foundation Trust (CMFT) 
and Salford Royal Foundation Trust (SRFT). The objective regarding the patient recruitment 
of the wider study is set to reach an overall number of 200 patients with traumatic injuries, 
accumulated from both hospitals.  
For the Master by Research position, the data for a total 80 patients from both hospitals for 
IL-4, IL-6, IL-10 and IL-12 concentrations was analysed. 
The request of ethical approval for the research study was accepted and fully approved by 
Local Ethics Research Committee Manchester, NHS/HSC Research and development offices- 
IRAS project ID 172620- and the Ethical Committee at the University of Salford, under ethics 
code ST1617-17.  
2.1.1 Recruitment criteria for participation in the research study   
The participants for the research study were recruited by a team of research nurses from 
Central Manchester Foundation Trust (CMFT) and Salford Royal Foundation Trust (SRFT)).  
An informed consent was obtained from the participants in conformity with the Mental 
Capacity Act (2007) (Appendix 1). The participants are allowed to withdraw from the study at 
any time if they wish to do so later and the samples are promptly destroyed from the 
biobanks. The suitability for participation in the research study is checked against a pre-set 
criterion as shown in table 7. 
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Table 7: Recruitment criteria 
 
ISS-injury severity score 
The patients who meet the recruitment criteria will have 20 ml of venous blood collected 
within 24 hours of the injury. The protocol for this project provides that the collection of the 
same quantity of blood will be repeated for the day 3 (third day after traumatic injury) and 
day 5 (the fifth day after traumatic injury). Standard operating procedures and rigorous staff 
training were put in place to ensure homogeneity of the process and the integrity of the 
sample biobank resource. 
Clinical data was collected for the days matching blood collection, and either in addition to 
an extra time point at day 8 following traumatic injury. The data collection sheet is shown in 
the Appendix 2. All blood samples and clinical data were collected ensuring that patient 
anonymity was respected at all times by using only a BIT identifier as per ethical stipulations. 
Moreover, all the data obtained from blood collection and analysis are stored under  
In this study, IL - 4, IL - 6, IL - 10 and IL - 12 concentrations in the blood serum will be tested 
for D1 and D5 collection points and compared against SOFA score in the respective days. A 
SOFA score ≥ 3 for one organ system is considered as failure of this organ (Vincent et al., 
1996; Frohlich et al., 2016). For this analysis, each serum sample had also D1/D5 ratio 
calculated for each cytokine concentration separately. The result obtained as increase or 
decrease in concentration are separated in two groups with a particular cut-off for each 
Age > 16 and <90 Years
Gender M/F
ISS > 15
Immediate surgical
intervention
ICU admission
Recruitment criteria
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cytokine to show the most visible changes. The two groups are then used to predict a clinical 
outcome correlated to SOFA score in D5. 
These findings were taken in consideration for data analysis. Therefore, a patient with poor 
outcome is considered to have a SOFA score ≥ 3. C-reactive protein concentrations will be 
compared against IL - 4, IL - 6, IL - 10 and IL - 12 concentration, to find any correlation with 
the clinical outcome.  .  For our analysis, the patients were clustered in 2 groups at a cut-off 
of 100mg/l concentration of CRP in D5. The groups were further compared against the 
concentration of IL - 4, IL - 6, IL - 10 and IL - 12 in D1 to observe if they can be used as 
biomarkers of poor outcome. 
The primary aim of this study was to investigate the hypothesis that immune imbalances (a 
hyperactive CARS response) result in the late phase ( D5 post admission and beyond) 
morbidity and mortality. It is then highly likely that subcellular fingerprints of this immune 
imbalance can be detected much earlier than the presentation of gross clinical sign. 
Identification and detection of such early biomarkers (D1 post admission), will enable the 
crucial stratification of the cohort of patients destined for poor outcomes in the later phase 
of major trauma.  
Early identification of patients at risk of developing sepsis is crucial in order to receive 
focussed, early clinical interventions. These analyses will help to determine the relationship 
between mentioned cytokines with the clinical outcome as predictive biomarkers. Elevated 
values for SOFA score are correlated to poor clinical outcome. A SOFA score higher than 3 
describes organ failure (Antonelli et al., 1999; Fueglistaler et al., 2010) whereas SOFA ≥ 6 
results in an increase in mortality rate of more than 25% (Lie et al., 2018; Shabir & Maqbool, 
2017).  
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2.2 Sample handling 
Patient blood samples are couriered to the University of Salford within 2-3 hours of 
collections. Serum is separated for cytokine detection and quantification. The serum is 
aliquoted and labelled appropriately and stored in the -80 annotated biobank until further 
experimentation. Peripheral blood mononuclear cells PBMCs are recovered for biobanking 
as described below and aliquoted for further use. 
2.2.1 Serum separation  
Major trauma patients are recruited following response to trauma calls by the research 
nurse teams at CMFT and SRFT. If the appropriate pre-specified inclusion /exclusion criteria 
are met, informed consent is obtained from the patient or next of kin, and the blood sample 
is collected and stored on ice. The research team at the University of Salford is informed and 
immediate transport of the sample is arranged. Once the blood sample has reached 
Cockcroft Building of the University of Salford, it transported to the laboratory for analysis. 
The first step in processing the sample is serum separation from whole blood. For this 
process 10 mls of patient blood were transferred in two 15ml centrifuge tubes and 
centrifuged at 2000rpm (644xg) for 5 minutes. The serum was collected and 300 µl aliquots 
was transferred to each 8 labelled cryovials, then stored at -80◦C in a blood components 
bank. The serum is used later for cytokines detection and quantification. 
2.2.2 PBMCs collection 
Peripheral blood mononuclear cells (PBMC) extraction is obtained by using Lymphoprep, 
which is a density gradient medium used for isolation of PBMCs. The isolation was obtained 
by carefully layering 5 ml of patient0-0 blood over 5ml Lymphoprep and centrifugation at 
1800 rpm (522xg) for 20 minutes. After centrifugation the layer of PBMCs formed at the 
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interface between serum and Lymphoprep was harvested and transferred in another 15ml 
centrifuge tube. The PBMCs were washed in phosphate-buffered saline (PBS) and 
centrifuged at 1200 rpm for 10 minutes. At the bottom of the tube a pellet of PBMCs was 
formed which was re-suspended in 1ml cryopreservation media. One millilitre of 
cryopreservation media was prepared from 900 µl fetal bovine serum (FBS) and 100 µl of 
dimethyl-sulfoxide (DMSO). The re-suspended pellet is transferred into cryovials placed in 
the container “Mr. Frosty” containing isopropyl alcohol, and then transferred in the freezer 
at -80◦C for further analysis. 
2.3 CYTOMETRIC BEAD-ARRAY (CBA) 
In order to detect and quantify the concentration for IL - 4, IL - 6, IL - 10 and IL - 12 from the 
blood serum, bead-based immunoassays were employed. CBA is a method of capturing an 
analyte with beads of known size and fluorescence, then detecting them using flow 
cytometry. The advantages of CBAs are that they are simple to deliver, they allow multiplex 
analysis of multiple proteins from a single sample. Moreover, a set of standards are provided 
to generate a standard curve for each analyte from where the concentration of the cytokines 
in unknown samples can be deducted. 
CBA kits used for cytokines detection were acquired from BD Biosciences and contain the BD 
CBA Human Soluble Protein Flex Set and Human Soluble Protein Master Buffer Kit. A BD 
FACSVerse flow cytometer which provides dual-laser 488nm and 640nm lasers was used for 
cytokines detection. Each CBA Human Soluble Protein Flex Set provides CBA standards 
necessary to create the standard curve for each cytokine separately, and also contains a vial 
of capture beads and PE detection reagent. The capture beads and PE detection reagent are 
provided at 50X concentration and need dilution before use. 
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2.3.1 CBA Standards preparation 
The BD CBA standards are provided in lyophilized form. For the start, the standards have to 
be reconstituted and serially diluted for use. The kit protocol was carried out according to 
manufacturer instruction. 
2.3.2 The analysis of IL - 4, IL - 6, IL - 10 and IL - 12 concentration in major trauma samples 
using cytometric bead assay 
For cytometric analysis, one tube with patient serum is retrieved from the blood 
components bank, stored at -80◦C. The sample is allowed to defrost on the bench at room 
temperature. Each serum sample was analysed in triplicate. Fifty microliters of patient 
serum were added to each tube, followed by 50 µl of mixed capture beads each, and mixed 
gently. The tubes were left for incubation at room temperature for one hour. 
Following one hour of incubation, 50 µl of PE detection reagent, prepared as shown for 
standards, was added to each tube and left to incubate for 2 hours, at room temperature 
and protected from direct light. Once the incubation ended, 1 ml of wash buffer was added 
to each tube and centrifuged for 5 minutes at 200xg. The supernatant was aspirated 
carefully to not disturb the pellet, then the pellet was resuspended in 300 µl of wash buffer, 
ready for flow cytometric analysis.  
2.4 - DETECTION AND QUANTIFICATION OF CYTOKINES OF INTEREST USING FLOW 
CYTOMETRIC TECHNIQUES  
FACS Verse flow cytometer (BD Bioscience, USA) with 488-nm and 640-nm lasers was used 
to detect and analyse blood samples collected from selected patients.  FACSuite software is 
used to operate the machine, acquire samples and analyse the data. The sample flow 
through the cytometer and is interrogated by a laser for the existing fluorescent antibodies. 
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The fluorescence is captured and expressed in data as median PE fluorescence intensity 
(MFI) which is used for analysis. 
2.5 Statistical analysis 
The data is presented as mean, ±  standard error of the mean for normal distribution and as 
median (inter quartile range) for non-normally distributed (Curran-Everett, 2008). Statistical 
analysis was performed to assess differences between the levels of cytokines from the blood 
collected in day 1 and from day 5, and also to observe relationship between the 
concentration of cytokines investigated in this thesis and clinical parameters such as SOFA 
score deduced from clinical meta data. Statistical analysis was performed using Minitab 
statistical software (Version 18, Minitab Inc. Pennsylvania State University, US). The 
deviation from Gaussian distribution was tested by Anderson-Darling test (Theodorsson, 
1988). For normally distributed data, Two-sample T test were used, whereas for non-
parametric data Mann-Whitney U-test was carried out. The statistical significance was 
determined at p < 0.05 level. 
3. RESULTS 
3.1 Optimization of the cytometric bead assay (CBA) for cytokine analysis 
In this study, triplicate cytokine analyses (IL - 4, IL - 6, IL - 10 and IL - 12) were carried out in 
day 1 and day 5 (D5) post-admission serum samples of major trauma patients admitted to 
Central Manchester Foundation Trust and Salford Royal Foundation Trust. The data was 
compared with a range of clinical and biochemical parameters documented on day 1 (D1), 
day 5 (D5) and day 8 (D8) post-admission. The raw data from the study is detailed in 
Appendices 8, 9, 10 and 11. 
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3.1.1 Cytometric bead assay set-up and fluorescence compensation 
The compensation was completed according to manufacturer’s protocols, an assay to test 
manufacturer’s standards of the relevant cytokines was created. Experiments for IL - 4, IL - 6, IL - 10 
and IL - 12 were carried out to generate standard curves. The standard curve formula was used to 
convert median fluorescence intensity of PE in order to derive the corresponding concentrations for 
the respective cytokines. The standardised method was then applied to the clinical samples collected 
in the study to calculate serum cytokine levels and investigate the correlation between the previously 
mentioned cytokines and clinical outcome following traumatic injury 
3.1.2 Optimization of IL - 4, IL - 6, IL - 10 and IL - 12 cytometric bead arrays 
For IL - 4, IL - 6, IL - 10 and IL - 12 analyses, new experiments were created either in duplex 
(IL - 6 and IL – 10, IL – 4 and IL – 12) or multiplex (IL - 4, IL - 6, IL – 10, IL – 12) mode. The 
experiments contained new tube settings for standard samples and new designed plots, 
where the population of beads were correctly gated. The populations of capture beads were 
first interrogated using P1, being corrected with minimal voltage adjustment on FSC and SSC, 
as seen in first plot in Figures 24A and 25A. When standard samples were acquired, the 
beads are identified in the individually allocated space, as seen in the second panel (Figure 
24B and 25B).  
A)                                  B)                                                          C) 
 
Figure 24. Duplex analysis for IL - 4 and IL - 12 
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Fig 24A. Gating of populations in P1, Fig 24B. relative positions in A5 for IL - 4 and E5 for IL - 12, Fig 24C. 
median fluorescence intensity of PE for IL - 4 and IL -12 standards. 
 
Each bead population has an alphanumeric position, indicating the position relative to other 
beads.  IL - 4 position can be found at position A5, IL - 6 at position A7, IL - 10 at B7 and IL - 
12 at E5, as seen in the second panel of Figures 24B and252B. Panels 24C and 25C show 
median fluorescence intensity of PE for each bead population interrogated in the second 
panel. 
A)                                     B)                                                     C) 
 
Figure 35: Duplex analysis for IL - 6 and IL – 10 
Fig 25A. gating of populations in P1, Fig 25B. relative positions in A7 for IL - 6 and B7 for IL - 10, Fig 25C. 
median fluorescence intensity of PE for IL - 6 and IL - 10 standards. 
Figures 26 and 27 represent the standard curves obtained for IL - 4 and IL - 12 standards 
respectively, while figures 35 and 36 show the standard curves obtained for IL - 6 and IL - 10 
standards. The standard curves were derived through a range of pg/ml concentrations of the 
standards on the x axis /and plotted PE-median fluorescence intensity on y-axis to deduce 
cytometric measurements. 
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Figure 26: IL - 4 standard curve 
 
Figure 27: IL - 12 standard curve 
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Figure 28: IL - 6 standard curve  
 
 
Figure 29: IL - 10 standard curve  
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The standard curves generated for the cytokines of interest (IL - 4, IL - 12, IL - 6 and IL – 10) 
were used for calculation of the concentration of respective cytokines in the serum of 
patients following traumatic injury. 
Multiplex analysis for IL - 4, IL - 6, IL - 10 and IL - 12 was used for measurement of PE median 
fluorescence intensity necessary for cytokine quantification in the serum collected from 
patients after a traumatic injury. As per optimised protocol, the whole population of capture 
beads is first interrogated in P1, then recognised and individually gated in their allocated 
alphanumeric positions, as seen in the second panel in figure 30. The third panel in figure 30 
shows the curve generated measuring median fluorescence intensity for PE. Median 
fluorescence intensity of PE values is further used to calculate the concentration of each 
cytokine individually, necessary for patient outcome analysis. The data verified that the 
sensitivity of the methodology was adequate to capture the cytokine levels in the patient 
serum. 
3.1.3. Optimisation of the multiplex analysis of IL - 4, IL - 6, IL - 10 and IL - 12 concentrations 
in the serum of patients following traumatic injury 
A)                                                  B)                                                        C) 
 
Figure 30: Multiplex analysis for IL-4, IL-6, IL-10 and IL-12 
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Fig 30A. gating of populations in P1, Fig 30B. relative positions in A7 for IL - 6 and B7 for IL - 
10, A5 for IL - 4 and E5 for IL - 12. Fig 30C. median fluorescence intensity of PE for IL - 6 and IL 
- 10, IL - 4 and IL – 12. Each population has a distinct colour which matches the curve generated 
for PE MFI.  
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3.2 DATA ANALYSIS FOR CYTOKINE IL - 4, IL - 6, IL - 10 AND IL - 12 CONCENTRATIONS IN 
THE SERUM OF THE PATIENTS FOLLOWING TRAUMATIC INJURY  
Comparison of D1 with D5 cytokine concentrations. 
Averaged cytokine concentrations deduced from the patient cohort (n=80) was compared  
on Days 1 and 5 using the either the Mann-Whitney U-Test or a 2 Sample T-test as denoted 
in the figures below.  
3.2.1 Interleukin - 4 concentration in serum sample from patients with taumatic injury 
 
 
 Figure 31: Mean IL - 4 concentrations (D1/D5 comparison) with standard error bars.  
 IL - 4 mean concentration in D1 was 3. 5083 pg/ml (range 2.9658 to 4.2648 pg/ml). IL - 4 
values for D5 in the same cohort showed a mean concentration was 3.6233 pg/ml (range 
2.4338 to 4.3709 pg/ml). The median value in D5 was 3. 6132. As shown in figure 31, a 
moderate but statistically significant increase in D5 compared to D1 was observed at p= 
0.031 using a 2 Sample T-test.
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3.2.2 Interleukin - 6 concentration in serum samples from patients with traumatic injury 
 
Figure 32: Averaged IL - 6 concentrations (D1/D5 comparison)  
The mean IL - 6 value for D1 was 181.6190 pg/ml , whereas in D5 was equal to 91.2001 
pg/ml. D1 values ranged from 0.8285 pg/ml to 3992.2299 pg/ml, whereas for D5, the values 
ranged from 0.2620 pg/ml to 4635.4485 pg/ml.  
Statistical analysis shows a significant difference between D1 and D5 (p=0.000) with a 
significant decrease in IL - 6 concentration in D5 as shown in the figure 32. (P-value obtained 
with Mann-Whitney U-Test). 
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3.2.3. Interleukin - 10 concentration in serum samples from patients with traumatic injury 
 
Figure 33: Mean IL - 10 concentrations (D1/D5 comparison)  
As shown in figure 33, there is a significant decrease in the IL - 10 concentration from D1 to 
D5 at a value of p = 0.000. (P-value was obtained with Mann-Whitney U-Test). The mean 
value of IL - 10 in D1 was 14.0563 pg/ml with values ranging from 1.4881 pg/ml to 79.4539 
pg/ml. IL - 10 mean concentration in D5 was 4.3129 pg/ml and the median value was 2.5558 
pg/ml. D5 IL - 10 concentration values ranged from 0.3064 pg/ml to 57.5793 pg/ml. 
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3.2.4. Interleukin -12 concentration in serum samples from patients with traumatic injury 
 
Figure 34: Mean IL – 12  concentrations (D1/D5 comparison) 
From the figure 34 can be seen a significant increase in the concentration of IL - 12 in D5, at 
p= 0.000, (P-value was obtained with Mann-Whitney U-Test). The mean value obtained in D1 
for IL - 12 concentration was 6.6956 pg/ ml, For D5 IL - 12 concentration, the mean 
concentration was 7.0324 pg/ml, the concentration values of D5 ranged from 6.1474 pg/ml 
to 10.9858 pg/ml. 
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3.3 Correlation between IL - 4, IL - 6, IL - 10 and IL - 12 concentration in D1 with SOFA 
scores in D5 and D8, as predictors of patient outcome 
3.3.1 Cytokines concentration in D1 compared to D5 SOFA score (threshold of 3) 
 
 
Figure 35: An overview of D1 IL - 4, IL - 6, IL - 10, and IL - 12 concentration associated with D5 SOFA 
score (threshold of 3)  
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Figure 35 present an overview for all 4 cytokine concentrations analysed in D1. SOFA score 
from D5 is employed to determine trends in early presence of cytokines in peripheral blood 
of trauma patient, to determine if these trends can be used as predictors for poor clinical 
outcome in later stages. 
A)                                                                      B) 
  
C) D) 
 
Figure 36: A comparison of cytokine concentration in D1 with D5 SOFA score (threshold of 3). (Mann-
Whitney U-test was used to compare the data clustered in the groups of SOFA <3 and SOFA ≥ 3) Data 
is presented as mean values with standard error bars) 
 As seen in Figure 36, all 4 cytokines are represented in 4 different panels, each one 
representing one cytokine analysis. Figure 36A shows a statistically significant increase in IL - 
6 concentration in D1 for patients which presented SOFA ≥ 3 in D5 (p=0.015), which suggest 
that higher value of IL - 6 in D1 might predict a poor clinical outcome. Figure 36B shows also 
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a statistically significant increase in IL - 10 concentration in D1 in the group of patients with 
SOFA ≥ 3 (p= 0.023). Figure 36C and 36D represent the data for IL - 4 and IL - 12, which show 
moderate differences between the two groups (SOFA < 3 and SOFA ≥ 3) but there are not 
statistically significant differences. (Mann-Whitney U-test was used to compare the two 
groups in each panel). 
3.3.2  Cytokine concentration in D1 compared to D5 SOFA score (threshold of 6) 
A)    B) 
  
C)                                                                                     D) 
 
Figure 37: A comparison of D1 cytokine concentration correlated to D5 SOFA score (threshold of 6). 
(Mann-Whitney U-test was used to compare the data clustered in two groups of SOFA <3 and SOFA ≥ 
3) 
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Figure 37 present all 4-cytokine concentration grouped separately at a threshold of 6 for 
SOFA score in D5. The threshold of 6 was chosen as it indicates that there is more than one 
organ starting to fail and increases the risk to develop sepsis with subsequent increased risk 
of death. These changes are reflected in the cytokine concentration changes and can be 
observed in each A), B), C) and D) panels in figure 37. Moreover, it can be observed that at 
the threshold of 6 for SOFA in D5, all our cytokines analysed show statistical deference 
between the groups sorted for SOFA score <6 compared with SOFA score ≥6. Figure 37A 
show a statistically significant increase in IL - 4 concentration when D5 SOFA ≥ 6 at p=0.025 
(2 Sample T-test).  IL - 12 is presented in figure 37B and shows a statistically significant 
decrease in IL - 12 concentration in the group of patients with D5 SOFA score ≥ 6 at p=0.025 
(Mann-Whitney U-test). Figure 37C and 37D shows that IL - 6 and IL - 10 presents with 
statistically significant increase in their concentration in the blood serum collected form 
patients with SOFA ≥ 6 in the 5th day of their hospital stay (p= 0.000 for IL - 6 and 
respectively p= 0.037 for IL - 10; Mann-Whitney U-test). 
 
3.3.3 Cytokine concentration in D1 compared to D8 SOFA score (threshold of 3) 
A) B) 
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C) D) 
    
Figure 38: A comparison of D1 cytokines concentration with D8 SOFA score (threshold of 3).  (Mann-
Whitney U-test was used to compare the data clustered in two groups for SOFA <3 and SOFA ≥ 3) 
 
As seen in figure 38, the four cytokines are presented separately to test their ability as 
predictors of poor clinical outcome in D8 after a traumatic injury.  From all 4 cytokines 
analysed, only IL - 6 and IL - 12 (38B and 38D) showed statistically significant differences 
between the concentrations clustered for D8 SOFA score at threshold of 3. The significant 
increase of IL - 6 concentration may predict a poor clinical outcome, as the higher 
concentration in D1 is associated to higher SOFA score 8 days after trauma (p=0.009, Mann-
Whitney U-test). IL - 12 also shows statistically significant decrease in concentration in D1 
and is correlated to higher values of SOFA score in D8 (p=0.000). No statistical significance 
was seen for IL - 4 and IL - 10 concentrations at threshold of 3 for SOFA score in D8. 
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3.3.4 Cytokine concentration in D1 compared to D8 SOFA score (threshold of 6) 
A) B) 
  
C) D) 
  
  Figure 39: A comparison of D1 cytokine concentration with D8 SOFA score (threshold of 6). (Mann-
Whitney U-test was used to compare the data clustered in two groups for SOFA <6 and SOFA ≥ 6) 
 
From figure 39B can be observed that there is a statistically significant increase in IL - 6 
concentration in D1 which correlates with high SOFA score in D8. Whereas IL - 12 
concentration (figure 39D) shows a statistically significant decrease in its concentration 
(p=0.037), which correlate with poor clinical outcome in D8 defined by SOFA ≥ 6. IL - 4 and IL 
- 10 show differences between D8 SOFA <6 and D8 SOFA ≥ 6, but the differences are not 
statistical significant. 
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3.4 D1/D5 ratio for cytokine concentration and SOFA score in D5, as predictor of clinical 
outcome 
3.4.1 IL - 4 D1/D5 concentration ratio and the association with D5 SOFA score 
A) B) 
 
Figure 40: IL-4 D1/D5 concentration ratio reflected in D5 SOFA score (mean values with standard error 
bars) 
The figure 40A shows that a decrease higher than of 7% in IL - 4 concentration from D1 to D5 
results in a decrease in D5 SOFA score. Therefore, lower concentration of IL - 4 in D5 is 
correlated with a better outcome, whereas in figure 40B an increase in IL - 4 concentration 
over 5 days is corelated with higher SOFA score, therefore a poor clinical outcome.  
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3.4.2 IL - 6 D1/D5  concentration ratio and the association with D5 SOFA score 
A) B) 
 
Figure 41: IL - 6 D1/D5 concentration ratio reflected in D5 SOFA score (mean values with standard error 
bars) 
From the figure 41A we can observe that a decrease of 75% in IL - 6 concentration over 5 
days of hospital stay, results in lower SOFA score, therefore a better clinical outcome. 
Whereas, an increase of 50% in IL - 6 concentration shows an increase in SOFA score with a 
poor clinical outcome, as shown in figure 41B. 
3.4.3 IL - 10 D1/D5 ratio and the association with D5 SOFA score 
A) B) 
  
Figure 42: IL - 10 D1/D5 concentration ratio reflected in D5 SOFA score (mean values with standard 
error bars) 
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A decrease of 50% in IL - 10 concentration over 5 days of hospital stay results in a decrease 
in SOFA score, as shown in figure 42A. The figure 53B shows the opposite to figure 53A, 
providing that 50% increase in IL - 10 concentration results in an increase in SOFA score in 
D5. Therefore, an increase in IL – 10 concentration over 5 days results in poor clinical 
outcome. 
3.4.4 IL - 12 D1/D5 concentration ratio and the association with D5 SOFA score 
A) B) 
.  
Figure 43: IL - 12 D1/D5 concentration ratio reflected in D5 SOFA score 
 
As figure 43A shows, a decrease in IL - 12 concentration higher than 2%  over 5 days, results 
in an increase in SOFA score, whereas the increase in IL - 12 over 5 days up to 10 % and over 
10 % results in higher SOFA scores. 
All 4 cytokines analysed presented changes in concentration over 5 day of hospital stay and 
have resulted in changes in SOFA score. A decrease in IL - 4, IL  - 6 and IL- 10 concentration 
show to be correlated with lower SOFA scores, therefore, they may predict a favourable 
clinical outcome. Whereas the increase in the mentioned cytokines is correlated with a poor 
outcome expressed as higher SOFA scores. On the other hand, D5 SOFA score show to be 
affected by too low levels of IL – 12 concentration and either by too high levels of IL - 12.   
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3.5.  The association between IL – 4, IL - 6, IL - 10 and IL – 12 concentration and C - 
reactive protein levels in trauma patients.  
As figure 44 show, there are different pictures of cytokines association to CRP. First, in figure 
44A can be seen that there is no correlation between IL - 4 concentration in D1  and CRP 
concentration in D5 as both groups have nearly equal values of IL - 4 concentration in D1. A 
different picture is seen in figure 44B, showing that lower levels in CRP concentration in D5 
are correlated with low levels of IL - 6 in D1.  
   A)                                                                               B)             
  
C) D) 
 
Figure 44: C-reactive protein concentration in D5 and the association with cytokine levels in D1 
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Figure 44C shows that high levels of IL - 10 concentration are associated with CRP levels 
higher than 100mg/l as the proxy measure for poor clinical outcome. The panel figure 44D, 
shows that higher levels of D5 CRP are associated with low levels of IL-12 concentrations on 
D1; similar results were described by Mold et al., in 2002. Overall, the results show that high 
levels of CRP in D5 are correlated to high levels of IL-10 and IL -6 and low levels of IL-12 in 
D1. The trends from this experiment did not show statistical significance, possibly due to the 
smaller cohort (n=30) of patients who had recorded CRP levels in their clinical metadata. 
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4. DISCUSSION  
Traumatic injuries are among the top causes of death and disability worldwide, carrying a 
substantial economic burden. Approximatively 5.8 million people die each year as result of 
traumatic injuries. Globally, trauma affects mostly younger, male populations, being the 
leading cause of death in the under 45-year-old population. There are more fatalities due to 
traumatic injury than malaria, TB and HIV/AIDS summed together. The most common 
traumatic injuries acquired are through penetrating wounds, blunt or burn injury (Sakran et 
al., 2012), with traffic accidents accounting for 19 % and violence for 12 % of total injuries 
(Patton et al., 2009). 
Major trauma continues to be a significant cause of mortality and morbidity in the UK. In 
England only, there are 20,000 major trauma cases each year resulting in 5400 deaths 
(TARN,2017). In contrast to global trends, the demographics of major trauma is recently 
reported to be changing quite significantly (TARN 2017). In UK, the median age of the 
patients presenting in hospitals with traumatic injuries has increased, showing that 42% of 
the trauma patients are over 65-years-old in contrast to the global patterns where young 
males predominate. The nature of the injuries has seen a shift as a result of this changing 
demographic. While the incidence of road traffic injuries continues as before, trauma 
resulting from falls of less than 2m in height increased to 47% of total major trauma injuries 
(N.H.S. England, 2018; Moran et al., 2018).  
The implementation of the new ‘Trauma care’ pathway which focus on specialised major 
trauma centres has saved many lives which otherwise would have resulted in fatalities. The 
19% percent increase reported in survival rates is attributed to this measure.  
Traumatic injuries initiate a cascade of physiological adaptations, comprising 
cardiorespiratory and immune systems with the aims of achieving and maintaining  
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homeostasis. A local and systemic inflammatory response syndrome (SIRS) develops in order 
to control the haemorrhage and the function of vital organs. Ideally, a counter anti-
inflammatory response syndrome (CARS) will replace the inflammatory state leading to an 
uneventful recovery (Keel & Trentz, 2004).  
However, a major traumatic injury induces an intense immune-inflammatory response which 
depends on the initial trauma load and triggers the local and systemic release of pro-
inflammatory mediators. A prolonged, intense pro-inflammatory state (overactivity of the 
SIRS response) leads to the development of early MODS, accounting for the early morbidity. 
On the other hand, an overwhelming hypo-inflammatory state from an overactivity of the 
CARS response may lead to immune-suppression that contribute to increased susceptibility 
to nosocomial infections and sepsis, which in turn result in late MODS and associated 
morbidity/mortality. Clinical evidence shows that another scenario has emerged comprising 
a persistent inflammation, immune suppression and catabolism syndrome (PICS) associated 
with poor clinical outcome (Gentile et al., 2012; Huber-Lang & Gebhard, 2016). 
After a traumatic event the level of pro- and anti-inflammatory cytokines is normally altered. 
There are many studies focused on finding immune-modulators that can predict the 
evolution of the clinical outcome after a traumatic injury. The most investigated cytokines 
which show predictive qualities for development of SIRS and MOF in polytrauma patients are 
TNF-α, IL - 6, IL - 10 and IL - 8 (Valparaiso et al., 2014).  
Investigating the cytokine concentrations over 5 days from the traumatic event and their 
correlation to clinical data will help to observe the trends in the cohort of trauma patients. 
Their quality as biomarkers of poor clinical outcome is investigated through comparison of 
the concentration of mentioned cytokines with SOFA score five days and eight days after the 
traumatic event. Serial measurements of serum levels were correlated to the severity of 
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organ dysfunction, time‐course changes, and associated with another marker of 
inflammation and injury severity C-reactive protein, in order to evaluate their clinical utility. 
Many of the published studies in major trauma have disadvantages with regards to small 
cohort sizes and single biomarker focus. While a significant body of literature pertaining to 
animal studies is available, there is increasing doubt cast on the translational relevance of 
such studies to humans. This study intends to analyse the predictive qualities of IL - 4, IL - 6, 
IL - 10 and IL - 12 in the development of complications after traumatic injuries, with the 
possibility of defining an early biomarker panel predicting poor clinical outcome in major 
trauma patient. The ability to stratify and identify such a cohort early in the post traumatic 
phase, will enable the focussed management of such patients with early, aggressive 
antibiotic treatments and thereby prevent the onset of complications. The inherent 
advantages of such a strategy in preventing antibiotic overuse are obvious. Furthermore, the 
ability to improve outcome in this cohort of patients will minimise the duration of hospital 
stays and have significant cost benefits for the NHS. 
Interleukin-6 
In this study, the serum IL - 6 concentration in D1 was compared with IL - 6 concentration in 
D5 to understand the general pattern of IL - 6 in the total cohort of patients. As expected, 
the mean concentration of IL - 6 in D1 was statistically significantly higher (p<0.001) than the 
concentration in D5, indicating a strong local inflammatory response early after injury.  
Studies on humans and animal model suggest that IL - 6 is a fast-acting cytokine and can be 
detected in high peaks in the first 24 hours after an traumatic event. It is associated to poor 
clinical outcome including mortality following traumatic injuries and its levels of 
concentration are correlated with the extent of tissue injury severity(Easton & Balogh, 
2014).   
116 
 
To understand the association between IL-6 concentrations and the evolution of the clinical 
picture, and to investigate its predictive capacities for clinical outcome, the concentration of 
IL - 6 in D1 was tested against SOFA score calculated for D5 and for D8. As seen in the 
literature review, SOFA score ≥ 3 is correlated to  single organ failure. This study shows that 
elevated levels of IL - 6 in D1 could predict poor clinical outcome in D5 (p = 0.015) and in D8 
(p = 0.009), when SOFA clustering was based at a cut off of ≥ 3. 
Secondly, it was investigated the relationship between the levels of IL - 6 as predictor of 
multiorgan failure and increased risk of death from sepsis expressed by SOFA score higher 
than 6. Indeed, it was found a relationship between higher levels of IL - 6 in D1 and SOFA 
score in D5, suggesting that the levels of IL - 6 in D1 may predict multiple organ failure in D5 
(p<0.001); similar results showing an association between high levels of IL - 6 in D1 and high 
SOFA score in D8 were also found (p= 0.020). The concentration of IL - 6 ranging from 225,44 
and 259.75 pg/ml may predict bad clinical outcome.  Similar findings sowing an association 
between high levels of IL - 6 and increased SOFA score were also reported by Shimazui et al., 
(2017) and Takahashi et al., (2016). Moreover, Giannoudis et all., 2008, showed in their 
study that the cut off of 200 pg/ml can be used as diagnostic of SIRS state, and the 
concentration higher than 300 pg/ml of IL - 6 is associated with increased risk of MOF and 
death. As the results from this study are in concordance with the statements presented 
previously, it seems possible to say that  IL - 6 may be a good biomarker for poor clinical 
outcome in traumatic injury. 
The trends for IL - 6 were maintained (although not statistically significant) when the 
analyses were based on C- reactive protein levels as a proxy of late phase sepsis/MOF in the 
major trauma cohort. This might be due to IL - 6 stimulating properties over the production 
of CRP; concluding that too high levels of IL – 6 in D1 might sustain increased levels of CRP 
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over many days (Del Giudice & Gangestad, 2018).  C-reactive protein is widely known to be a 
biomarker for inflammation and sepsis. CRP levels higher than 87 mg/l is associated with 
infection and with postoperative complication. Whereas levels of 100 mg/l and higher were 
associated with sepsis (Povoa et al., 2005). Higher values of CRP at D5 after surgical 
intervention is considered a marker of complications (Chapman et al., 2016). 
  In this study we intended to find correlations between the levels of IL - 6 in D1 and the 
levels of CRP in D5. While the trends corroborate our hypothesis, the lack of statistical 
significance is likely to be due to the reduced cohort size (n =30) where CRP levels were 
recorded.  
Interleukin-10 
With respect to the research question regarding the ability of IL - 10 to be used as an early 
biomarker of clinical outcome in patients with traumatic injuries, we first compared IL - 10 
concentrations in D1 with D5 in the major trauma cohort. It can be noticed that the higher 
levels of IL - 10 in Day 1 post trauma showed a statistically significant decrease in D5 
(p=0.000) with values of IL-10 in D1 of 14.06 pg/ml decreasing to 4.31 pg/ml in D5. This 
pattern is similar to the trend in IL - 6 concentration over the 5 days, showing that the pro-
inflammatory cascade is dampened down by anti-inflammatory mediators, such as IL-10 in 
the attempt to restore the homeostasis for host survival. (Sapan et al., 2016). 
The study went on to analyse the correlation between the levels of IL - 10 levels and SOFA 
score, in the attempt to observe if IL - 10 has predictive qualities or associations with poor 
clinical outcome. Similar to IL - 6 the patients were separated in to two groups on the basis 
of SOFA scores (cut off at 3 and 6) and were compared to observe the trends. High levels of 
IL - 10 concentration in D1 correlated significantly patients with high SOFA score in D5 at 
both cut off thresholds studied (p = 0.023 and respectively p = 0.037). These findings may 
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suggest that high levels of IL – 10 early in the post traumatic phase could indicate an adverse 
clinical outcome 5-8 days later and predict the cohort destines for poor clinical outcomes 
after a traumatic injury. There is  evidence to suggest that abnormal (high) levels of IL - 10 
concentrations might be due to IL - 10 gene polymorphisms present in some of the patients,  
making them prone to develop sepsis. The promoter of single nucleotide polymorphism 
(SNP) at position -1082 of IL - 10 gene has been found associated to a different production of 
IL - 10 and to susceptibility to sepsis and severe prognosis after septic shock (Palumbo et al., 
2012). Moreover, Muehlstedt et al., (2002) reported that high IL - 10 was found in patients 
with lung injuries showing higher predisposition to nosocomial infections; therefore, the site 
of injury might be relevant when evaluating the immunologic status. 
IL - 10 concentration in D1 was also tested against CRP in D5. Studies on humans and animal 
model have found that increased CRP concentration is related to adverse trauma 
progression (El- Ashker et al., 2014; Jiao et al., 2016). Once the patient improves and is 
successfully treated, the levels of CRP decrease accordingly. However, continually increased 
levels of CRP is related to a predisposition to complicated infections. In this study, the higher 
levels of IL - 10 concentration in D1 were correlated to CRP levels higher than 100 mg/l in D5. 
Similar correlations between levels of IL - 10 and CRP were presented by Jiao et al., (2016), 
showing that this correlation can be used predict progression and prognosis in trauma 
patients. 
Interleukin-4 
To observe the trends over 5 days of IL - 4 levels, the concentration in D1 was compared to IL 
- 4 levels in D5 (Figure 38). This comparison showed a moderate but statistically significant 
increase in IL - 4 values in D5 (p=0.031) for the full cohort. These results are in agreement 
with those obtained by Cohen et al., (2011) showing that low levels of IL - 4 at admission are 
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associated with the immediate reaction to acute injury when the levels of pro-inflammatory 
cytokines increase in attempt to fight the infection. The increase in IL - 4 concentration in 
later stages is correlated with the role of IL - 4 in suppression of pro-inflammatory mediators 
and restore the homeostasis. IL - 4 is secreted by Th2 helper cells and is depressed when the 
level of pro-inflammatory cytokines increase. Increase in IL - 4 in later stages of the immune 
response induces suppression of pro-inflammatory cytokines (Volpin et al., 2014). On the 
other hand, Torre et al., (2000) showed that higher levels of IL - 4 at admission were 
correlated with patients developing SIRS and were generally associated with younger aged 
patients , whereas lower levels of IL - 4 were associated with patients with higher age.   
As with other cytokines analysed until now, the next step is to determine if IL - 4 can be used 
as biomarker and to predict the clinical outcome in patients following a traumatic injury. 
Similar to the other cytokines’ analysis in this work, the trends in IL - 4 concentration were 
observed  to enable stratification the patients in two groups regarding SOFA score at a 
threshold of 3. High levels of IL - 4 in D1 were found to be correlated to SOFA score ≥ 3 in D5, 
but the increase is not statistically significant. However, a statistically significant difference 
between the levels of IL - 4 in D1 at SOFA score ≥ 6 in D5 was observed (p= 0.025), showing 
that higher levels of IL - 4 in D1 are associated with higher SOFA scores in D5, indicating the 
Day 1 IL - 4 levels is a better discriminator of more ill patients. The work corroborates studies 
which have shown that high levels of IL - 4 correlate to MOFS, sepsis  and with higher risk of 
mortality (DeLong & Born, 2004).  
Further, we show that an increase of over 10 % in IL - 4 concentration over 5 days are 
associated to SOFA scores higher than 6. These results are in line with those of previous 
studies which shows that the levels of IL - 4 are higher in severe trauma than in moderate 
traumatic injury (Volpin et al., 2014).  
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Biomarkers are used for diagnostic and prognostic to determine the presence of disease or 
biological state.  IL - 4 and IL - 6 were shown to be promising biomarkers for the detection of 
infection after reparatory joint intervention following traumatic events (Alvand et al., 2017).  
According to these findings, we can infer that highest levels of IL - 4 in D1 might be used as 
potential biomarker for predicting the development of SIRS in traumatic injury and a poor 
clinical outcome. However, in contrast with these results, other studies have found no 
correlation between IL - 4 and the severity of injury or the clinical outcome (Surbatovic et al., 
2007). When IL - 4 levels were analysed in correlation with CRP levels, the study did not find 
any differences.   
Interleukin-12 
IL - 12 concentration in D1 was compared to IL - 12 concentration in D5 to assess differences 
between D1 and D5 IL - 12 concentration. The comparison showed a statistically significant 
increase in concentration of IL - 12 in D5 compared to D1(p<0.001). In this study levels of IL - 
10 were found to be higher in D1 and the levels of IL - 12 were lower. These findings are 
consistent with those in other studies  such as Ertel et al., (1997), which showed in their 
research that low levels of IL - 12 might be correlated with higher values of anti-
inflammatory mediators, such as IL - 10, IL - 4 and TGF-β. Furthermore, Wick et al., (2000) 
showed that normal or increased values of IL - 12 are correlated to survivors from traumatic 
events 
The predictive abilities of the clinical outcome for IL - 12 were analysed in the next step. As 
for other cytokines, the patients were stratified in two groups according to SOFA score. The 
analysis showed that patients who showed lower values of IL - 12 in D1, presented higher 
SOFA score in D5 and D8. A decrease in IL - 12 concentration of more than 2 % over 5 days  
correlated with adverse outcomes. Similar findings were also reported by Koller et al., (1998) 
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showing that overall, after trauma the systemic IL - 12 show to be increased in non-septic 
patients and decreased in the patients who developed MOF. 
Statistical analysis showed a significant association between lower values of IL - 12 with 
SOFA ≥ 6 in D5 (p=0.023). It was also found a statistically significant decrease in IL - 12 
concentration in the groups at SOFA score ≥ 3 in D8 (p<0.001) and a decrease in 
concentration of IL - 12 in the group at SOFA  ≥ 6 (p=0.037). In concordance with the present 
results, previous studies have demonstrated that lower levels of IL - 12 are correlated with 
multi-organ failure and high risk of dying from multiple organ failure  (Wick et al., 2000). The 
data indicates that high IL - 12 levels in Day 1 are suggestive of a good clinical outcome or 
progression. Animal models have shown that in mice , survival has increased with IL – 12 
administration, but IL -12 neutralization resulted in high mortality (DeLong et al., 2004). 
 Moreover, studies regarding the abilities of lymphocytes to produce IL - 12 after traumatic 
injury showed a decreased number of IL - 12-producing monocytes on D5 post injury which 
correlates with the development of MOF (Spolarics et al., 2003; Reikeras et al., 2014). These 
findings broadly supports the work of other studies regarding low levels of IL - 12 and their 
correlation with the development of ARDS, sepsis, predisposition to infection and generally 
adverse clinical outcome in trauma patients (Hensler et al., 1998; Spolarics et al., 2003; 
Bozza et al., 2007).  
Further, the correlation of IL - 12 concentration with CPR is investigated. In this study the 
results show that low levels of IL - 12 are associated to higher levels of CRP ≥ 100mg/l, which 
in turn show a relationship with the development of sepsis. Therefore, low levels of IL-12 
concentration are associated to high SOFA scores and with high levels of CPR, predicting the 
development of ARDS and sepsis. The trends from this experiment did not show statistical 
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significance, possibly due to the smaller cohort (n=30) of patients who had recorded CRP 
levels in their clinical metadata. 
 Overall, these results show that patients developing an adverse outcome present subnormal 
levels of IL - 12, whereas non-septic patients have increased levels of IL - 12. Following these 
analysis, high IL - 12 levels might be a good biomarker predicting good clinical outcome 
following traumatic injuries. 
One limitation of this study was the delay in the retrieval of clinical meta data regarding the 
type of injury and length of stay, the type of organs affected by injury, further surgical 
intervention or about the blood loss during the incident. Although comparative data from 
Days 1-8 showed interesting trends, the lack of a cohort of controls similar to the normal 
heterogenous patient population from Greater Manchester was not available. Hence, the 
desirable a comparison with the normal levels of cytokines could not be carried out. 
For the D1 samples, some variation would have been introduced as a result of clinical 
interventions including administering fluids or blood transfusion etc. The resulting 
haemodilution could introduce variations in the levels of  cytokines, particularly for the 
cytokine that prevail at low concentrations in the serum. 
Defining the profile of cytokines in trauma patients can help to observe and understand the 
different patterns in immune responses associated with the evolution of the clinical 
outcome. Multiplex analyses used in this study imply that having a wide panel of possible 
predictive biomarkers can help to detect the onset of sepsis and to stratify the patients in 
order to receive adequate health care. This will prevent the development of complications 
and ensures a better recovery from their injuries. 
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The current study has shown interesting overall trends for IL - 6, IL - 10, IL - 4 and IL - 12 
cytokines in relation to their expression and association with clinical outcome in the later 
post traumatic phase. A parallel study conducted by Dr. Allarakia, (2018, data not published) 
on the same cohort of patients, showed that a high levels of T-reg cell expression 
(CD25+/CD127-) correlated with poor clinical outcome cohort resulting from immune-
suppression. Treg cells are instrumental for driving immunosuppression through dampening 
of the T cell response. These findings together with low IL - 12 values, high IL - 10 and IL - 4 
show a tendency towards immune-suppression in this cohort of patients presenting with 
higher SOFA scores in D5. Admittedly, the increased levels of IL - 6 for the same cohort 
shows a persistent pro-inflammatory status. These findings might suggest the presence of 
the newer phenotype described as ‘persistent inflammatory-immunosuppressive and 
catabolic syndrome’ (PICS). 
The syndrome is characterised of high levels of IL - 6 and IL - 10, reduced effector T-cell 
function, elevated levels of C-reactive protein, length of hospital stay > 14 days, neutrophilia 
(Rosenthal & Moore, 2015). Another factor that defines PICS is that the phenomenon is 
more common to patients > 65 years of age. The data from the Trauma Audit research 
network (TARN) shows the shifting demographic in the UK whereby 42% of the major 
trauma patients are over 65 years old and suffering from multiple co-morbidities, with 
increased susceptibility of developing PICS. In support to this supposition is the data on 
length of hospital stay for the cohort of patients in this study, which shows that the average 
hospital stay is 41 days. 
To fully define the presence of PICS syndrome for our trial, further research should include 
more cytokines profiles, such as IL - 8 and IFN-γ on the side of pro-inflammatory mediators, 
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IL - 13, TGF-β and IL - 17 as anti-inflammatory cytokines. This analysis could provide more 
definitive information regarding the presence of PICS. Unfortunately, the levels of albumin 
necessary to determine protein catabolism were not included in the data collected by the 
hospitals to support this hypothesis. It will be interesting to have a further check point at six 
months after initial injury and to collect further data to confirm or reject the hypothesis of 
presence of PICS syndrome.  
Enormous investments in clinical research in the last decade has led to significant 
improvements in trauma and critical care services, resulting in better understanding of the 
underlying pathophysiological processes and higher survival rates for trauma patients 
(Dewar et al., 2009). However, the survival of severely injured trauma patients showed a rise 
in incidents of multiple organ failure. Despite the improvements in treatment strategies and 
a better understanding of the syndrome, multiple organ failure still continues to result in 
poor patient outcome, long ICU stays and high mortalities (Ciesla et al., 2005). An early 
biomarker-based warning system developed as a Point of Care diagnostic, could indeed 
make a difference. 
At the time of conclusion of this study, the recruitment of patients for the clinical trial was 
still active, with the goal of achieving a complete cohort of 200 patients. The experiment 
described in this thesis was developed on 80 patients only, recruited from Central 
Manchester Foundation Trust (CMFT) and Salford Royal Foundation Trust (SRFT). Therefore, 
the data must be interpreted with caution and validated in the wider cohort of 200 patients. 
The findings presented are promising and could potentially have important implications in 
stratifying patients for better clinical management, improving clinical outcomes and 
minimising associated NHS costs.   
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However, there is abundant room for further progress in determining a wider panel of 
biomarkers and defining correlations between them.  
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CHAPTER 7: APPENDICES 
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Appendix 2 – Clinical data collection sheet. 
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Appendix 3 – Day 1 - clinical data for the patients recruited on Central Manchester 
Foundation Trust.
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Appendix 4 - Day 5 - clinical data for the patients recruited on Central Manchester 
Foundation Trust. 
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Appendix 5- Day 8 - clinical data for the patients recruited on Central Manchester 
Foundation Trust 
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Appendix 6 - Day 1 – clinical data for the patients recruited on Salford Royal 
Foundation Trust 
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Appendix 7 - Day 5 – clinical data for the patients recruited on Salford Royal 
Foundation Trust. 
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Appendix 8 - Day 8 – clinical data for the patients recruited on Salford Royal 
Foundation Trust 
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Appendix 9 - Interleukin-4 concentration, SOFA scores and C-RP concentration. 
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Appendix 10 - Interleukin-6 concentration, SOFA scores and C-RP concentration. 
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Appendix 11 - Interleukin-10 concentration, SOFA scores and C-RP concentration. 
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Appendix 12 - Interleukin-12 concentration, SOFA scores and C-RP concentration.
 
